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Abstract: 
The blood coagulation cascade is activated under various circumstances such as an 
injury. This system involves a tightly regulated series of events. The enzymes involved 
assemble with their respective cofactors on lipid membranes to reach their full pro-
coagulant complex potential. The coagulation cascade is divided into intrinsic and 
extrinsic portions, both of which converge into a common pathway with the activation 
of factor X (FXa). FXa is a very important part of the blood coagulation cascade because 
its activation is primarily responsible for thrombin generation. Activation of FXa alone is, 
however, insufficient to produce a fully active thrombin. For this to occur, FXa must form 
a complex with its protein cofactor Factor Va and its protein substrate prothrombin on a 
phospholipid surface. This suggests that the topography of the enzyme on the lipid 
surface changes when in a fully pro-coagulant state. However, the topography of FXa 
alone and in complex with these cofactors is poorly understood. Kunitz-type protein 
inhibitors, such as basic pancreatic trypsin inhibitor (BPTI), are globular proteins, which 
inhibit serine proteases such as FXa. These small protein inhibitors fit just inside the 
active site of the enzyme, making them ideal candidates with which to study the active 
site of FXa. The goal of this project is to gain understanding of the topography of fully 
active FXa by using lipid-anchored BPTI with linkers that act as molecular rulers to 
measure the range of reactive heights of the active site of FXa in its pro-coagulant 
complex on a phospholipid surface. 
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Introduction 
Hemostasis 
Hemostasis is the process responsible for initiating and terminating the blood 
clotting mechanism upon injury (1) . It is a tightly regulated and dynamic process by 
which bleeding as a result of vessel damage is stopped and, ultimately, returned to 
normal (1-3) .  The hemostasis process works to maintain blood in a fluid, clot-free state 
under normal conditions, form a solid clot to block bleeding upon injury, and then 
return blood to a fluid state upon repair of that injury.  This process involves a subset of 
processes including blood clotting, platelet activation, and vascular damage repair (3). 
Coagulation is the first integral part of this process as it is the formation of blood clots 
which assist with sealing the injury and returning blood flow to normal (2-4) . The 
coagulation cascade includes three major components some of which circulate in the 
blood in a deactivated state and become activated upon vascular injury. These 
components are platelets, vessel endothelium, and coagulation factors.  Platelet 
activation is important in hemostasis for sealing vessel damage and accelerating the 
coagulation system overall. Vessel repair is a result of the hemostatic plug composed of 
fibrin and platelets that seals the damage as well as endothelial components which 
repair the tissue (3). To understand more about the blood coagulation cascade, it is 
important to investigate the blood components involved more closely.  
Platelets 
Platelets are specialized blood cells that play an important role in hemostasis (2, 
5, 6). The structure of both the un-stimulated and stimulated platelet is important in its 
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functioning.  In a deactivated state, they are small, disk-like, non-nucleated cell 
fragments of megakaryocyte cytoplasm in the blood (6). When activated, platelets 
structure morphs from smooth and discoid to rough cells with pseudopodia. As the term 
suggests, these pseudopodia are feet-like projections which serve as puzzle-like sites of 
attachment for other platelets and fibrin. The cytoplasm is surrounded by a plasma 
membrane constructed in an open canalicular system (6). This system transports 
nutrients in and out of the cell. The plasma membrane is composed of over 30% 
phospholipids and nearly 60% proteins. The phospholipids are organized as a bilayer 
with polar head groups on both the external and internal layers in addition to a 
hydrophobic center. Neutral phospholipids like phosphatidylcholine are oriented on the 
external layer while anionic phospholipids are oriented internally. These phospholipids 
include phosphatidylserine, phosphatidylinositol, and phosphatidylethanolamine (7) . 
Tasks assigned to the phospholipids include solubilizing cholesterol such that cholesterol 
can maintain the fluidity of the phospholipid bilayer. A small percentage of 
carbohydrates are present in the membrane in the form of glycoproteins and 
glycolipids. 
The outer layer of the bilayer contains a glycoprotein complex known as the GPI 
complex. There are subgroups of glycoproteins involved in this complex: GPIa, GPIb, and 
GPIIb/GPIIIa. These proteins work together to attach platelets to collagen and bind von 
Willebrand factor.  This step-wise process involves the platelet exposure to coagulation-
inducing proteins, adhesion, and cellular reorganization. A well-characterized 
coagulation factor named von Willebrand factor (vWf) attaches to a receptor on the GPI 
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complex during platelet adhesion. vWF is a multimer produced by endothelial cells and 
megakaryocytes which is composed of over 200,000 subunits connected by disulfide 
bonds which functions with coagulation factor VIII to assist in platelet adhesion (5, 8, 9). 
This complex plays a necessary role in the conformational changes and overall activation 
(i.e. pseudopodia, increases in surface area) platelets undergo after stimulation (10). 
GPIa is a receptor protein. It attaches to extracellular collagen exposed at the site of 
injury. Next, GPIb then becomes exposed to vWF. Another structural shift in platelets 
occurs which allows for GPIIb and GPIIIa to bind with vWF and collagen.  This process is 
depicted in Figure I. 
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Figure I. GPI Complex. Depicted above is the phospholipid bilayer of a platelet cell 
containing GPIa, GPIb, GPIIb, and GPIIIa subunits and the step-wise platelet 
activation process. Adapted from (20) 
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 The internal membrane of platelets has been likened to the sarcoplasmic 
reticulum of muscle cells because they contain dense tubing, mitochondrial membranes, 
and storage granules (11). These storage granules serve to release necessary 
components to platelet adhesion when needed and are divided into different categories 
including α, δ, and λ types. Enzymes including phospholipase A and cyclooxygenase 
assist in the transfer of Ca2+ from membrane stores within the platelet to the cytosol 
encouraging secretion from the storage granules (5). The α-granules contain fibrinogen, 
which upon vessel injury is later cleaved to become fibrin necessary for the hemostatic 
plug. Alpha granules also contain proteins like β-thromboglobulin. One of its functions is 
to assist in megakaryocyte maturation and therefore in platelet production. The δ 
granules also known as electron-dense storage granules contain metabolically-
inactivated adenosine diphosphate or ADP (an agonist in platelet activation), serotonin 
(a common neurotransmitter), and calcium (metal ion involved in aggregation). Lambda 
granules contain lysosomal enzymes such as acid hydrolase important for the 
breakdown of waste materials (12).  
Activated platelets undergo conformational changes as a result of contact with 
endothelial components. Under normal circumstances, the endothelial lining of the 
vessels is inert and platelets are not stimulated to adhere. When the blood vessel is 
damaged, platelets are exposed to subendothelial components including collagen, tissue 
factor, fibronectin, and glycosaminoglycans. Then, platelets undergo adhesion in which 
they attach to these macromolecules in subendothelial tissues at the point of injury. 
This collection of cells forms what is referred to as the ‘adherent layer’ (7) . In response 
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to the initial platelets’ activation, other platelets aggregate to form a hemostatic plug (2, 
6). 
Aggregation is subcategorized into primary and secondary stages. Primary (1°) 
aggregation is a reversible process that arises from the stimulation (i.e. signaling) other 
platelets receive from the adherent layer.  While platelets are aggregating with one 
another, they are also undergoing a process called secretion which stimulates the 
irreversible secondary (2°) aggregation. Like many biochemical processes, aggregation 
requires divalent cations such as Mg2+ or Ca2+ to function properly (6) . Platelets release 
several vasoactive amines and other important substances, including but not limited to 
ADP, β-thromboglobulin, epinephrine, and platelet-derived growth factor (6). 
Epinephrine, a hormone and neurotransmitter, binds to α-adrenergic receptors on the 
platelet surface thereby encouraging stimulation (13).  The process is broken down into 
two major steps. First, storage granules cluster at the center of each platelet 
surrounded by microtubules. Then, the granules travel along the microtubules to the 
surface of the cell and fuse to the surface membrane and release their contents. The 
amount of substances released is dependent on the agonist involved as established by 
Kinlough et al. (14). Secretions such as these trigger other platelets in the area to adhere 
and continue forming the hemostatic plug.  
Plug formation and pro-coagulant activity on platelet surfaces assists in the 
generation of the thrombin burst which leads to fibrin formation. Fibrin complexes with 
the platelets to form the fibrin clot in the final stages of coagulation. As wound healing 
takes place, both the platelet aggregate and fibrin clot are broken down over time in a 
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process called fibrin clot retraction  (2, 6, 13, 15, 16). This process is also mediated by 
platelets. All of these components are part of an intricate stimulatory signaling pathway, 
which communicate messages to the platelets upon injury. There are also inhibitory 
components as well. One such pathway would be the adenylate cyclase enzyme 
complex. Adenylate cyclase and cyclic adenosine monophosphate (cAMP)-dependent 
phosphodiesterases work closely with one another to inhibit platelet function. These 
enzymes recruit the second messengers to attach to receptors on platelet surfaces 
sending signals to essentially de-activate each platelet cell (17).   
Vasculature Walls 
In addition to platelets, the vascular wall is an important component of blood 
coagulation. In general, blood vessels contain 3 layers: tunica intima, tunica media, and 
tunica adventitia (18). The tunica intima is the innermost layer composed of endothelial 
cells. The tunica media is the smooth muscle layer, which also contains elastic tissue as 
well. The tunica adventitia is composed of connective fibrous tissue. When the vessels 
are damaged, endothelial components such as tissue factor (TF) come in contact with 
platelets in the blood thereby activating them (2). Tissue factor, also known as factor III, 
is a protein that becomes exposed to intracellular blood components upon injury. It will 
be discussed further in subsequent sections. Coordinated interactions among these 
tissue components, plasma proteins, and platelet receptors lead to the primary 
hemostatic plug, which seals the damaged region of the vessel (2).  
Ashford et al completed an electron microscopy study on particular endothelial 
components and the role they play in coagulation (19).  The study was completed in vivo 
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in rats in which the vascular wall was manipulated and known endothelial components 
introduced, altered, or removed via purification.  
Microscopic evidence indicates that platelets in proximity with fibrin were visibly 
altered and showed loss of granulation. Conversely, even with vascular injury, platelets 
that are not in close proximity to the fibrin remained intact. After a length of time 
neutrophils (known inflammatory responders) were recruited to the injured area. The 
study investigated activity around disrupted endothelium in the presence and absence 
of ADP, collagen, and thrombin. Data suggested that adding ADP induced platelet 
aggregation. Evidence indicated that collagen adheres rapidly to platelets after trauma. 
It also suggested that collagen encouraged the release of ADP. Another interesting 
finding was that cAMP exhibited inhibitory effects on platelets.  Overall, the study 
surmised that the endothelium plays a passive barrier role separating circulating 
procoagulants in the blood from tissue-embedded activators necessary for the 
hemostatic plug.   
Other endothelial components include vWf and fibrinogen. As mentioned, vWf is 
a large multimeric plasma protein, which mediates platelet adhesion by binding them to 
the collagen at injury sites on the damaged vessel (2, 6).  Riddel et al (2) explored 
theories in blood coagulation by reviewing multiple studies that compared the accepted 
extrinsic/intrinsic model to the cell-based model theories proposed more recently. This 
publication describes vWF as an indispensable part of platelet-platelet interaction. Its 
primary role is to increase the efficiency of platelet attachment to one another. Its 
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secondary role is important for the survival of coagulation factor VIII described further 
in the Non-Enzymatic Factors section below.  
 
Coagulation Factors 
Serine Proteases 
The coagulation factors are proteins developed by hepatocytes and are another 
portion of the cascade necessary to form a clot (20).  Early work by Orwen, Biggs, and 
MacFarlane in the 1940s demonstrated that many of the coagulation factors are the 
zymogen form of serine proteases important in clot formation that required activation 
to function properly.  
Coagulation proteins are proteases activated by proteolytic cleavage. Many of 
these proteins are vitamin-K dependent. Vitamin K is necessary for -carboxylation of 
glutamate residues on the protease necessary to allow attachment to the membrane. 
The process of γ-carboxylation involves the reduction of vitamin K to vitamin KH2 by the 
enzyme, quinone reductase (15). Vitamin KH2 serves as a co-factor for carboxylase 
enzymes within hepatocytes that add a carboxyl group to the glutamate (Gla) domain on 
these serine proteases (15, 20-22) . Cleavage is a biochemical process by which one 
enzyme cleaves a portion of another enzyme adjusting its chemical composition 
converting it from an inactive state to an active one. Serine proteases are proteins 
which activate one another by this process. Because there are so many coagulation 
factors and more being discovered all the time, this publication will focus on discussing a 
select few in an effort to provide a general overview of their diverse characteristics.  
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Table I contains an abbreviated list of known serine proteases and their main functions 
(20).  
Coagulation Factors: 
Serine Proteases 
Function 
Factor II 
Prothrombin 
When cleaved becomes thrombin 
Cleaves fibrinogenfibrin 
Factor VII 
Proconvertin 
Forms complex with Tissue Factor to partially 
activate fX and FIX 
Factor IX 
Christmas Factor 
Partially activates fX  
Factor X 
Stuart-Prower Factor 
Cleaves prothrombinthrombin 
Factor XI 
Plasma Thromboplastin 
Antecedent 
Partially activates fIX 
 
The activation of these factors leads to the initiation of thrombin cleavage. 
Thrombin, a serine protease, is the activated form of coagulation factor II.  Its main 
responsibility is to cleave soluble fibrinogen, also known as factor I, converting it to 
insoluble strands of fibrin. Fibrin sticks together with blood components including 
platelets to seal the injured site. Previous work has established that hemostatic 
constituents among vertebrates, including prothrombin, are conserved suggesting that 
any vertebrate with a circulatory system contains these factors within that system (3, 
23). 
 
Non-enzymatic Factors 
Factor III, often called Tissue Factor, was mentioned earlier to complex with fVII 
in order to partially activate both fIX and fX. It is produced by endothelial cells and is, 
therefore, categorized as a member of the extrinsic pathway. Two distinct coagulation 
Table I. Serine Proteases and their Functions 
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pathways–extrinsic and intrinsic—work together to maintain hemostasis upon injury. 
After each participant of pathway has been activated and performed its task, the 
cascades enters a third pathway called the Common Pathway in which the components 
necessary to generate thrombin are fully activated. Factor VII complexes with non-
enzyme participant TF and performs its duties on the surface of TF-bearing cells (20).  
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 Figure II. TF Interaction on the Cell Surface during Coagulation. Depicted 
above is the interaction of tissue factor, factors Va, VIIa, and Xa with the 
endothelial cell surface.  Adapted from (20) 
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This complex serves as a partial activator of factors IX and X respectively.   
Factor VIII is another factor necessary for the activation of fX. Factor VII 
complexes with fIX such that fX is cleaved to a fully active state. vWF is critical for fVIII 
survival. FVIII is a labile co-factor meaning that it is easily degraded.  vWF complexes 
with FVIIIa prolonging its presence in the blood so that it may attach to fIXa for fX 
activation. All three factors work together to cleave fII for a burst of thrombin 
generation.  
Pro-accelerin or factor V is a member of the prothrombinase complex necessary 
for fX to cleave fibrinogen. The interaction between fVa and fXa can be seen in Figure III. 
It is activated by trace levels of thrombin to catalyze its attachment to fX on cell 
membranes (20). Further information on the integral role of fV is discussed below. 
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Figure III. Prothrombinase Complex and fVIIIa/fIXa Complex. FVa .Adapted from 
(117). 
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Factor IXa activates fX partially by forming a complex with its co-factor fVIII then 
attaching to fX on the surface of platelets and endothelial cells. Its role is critical in 
encouraging the clotting cascade into the common pathway. In 1952, Rosemary Biggs 
and her colleagues published an article in the British Medical Journal regarding fIX (24).  
At that time, many of the common characteristics associated with coagulation factors 
were just being recognized. Biggs et al performed several case studies on patients 
exhibiting the blood disorder, hemophilia, but were unresponsive to traditional 
hemophilia treatments. These cases were all similar in that their bleeding issues could 
not be rectified with anti-hemophilic globulin (fVIII), Ca2+, or fVII—known to be critical to 
coagulation. The ultimate finding was that all cases were deficient in an unknown 
substance present in normal blood fractions. The unknown substance was identified as 
Christmas Factor named for case study 1 (24). Now, fIX and Christmas factor are 
synonymous with one another (20). Further studies by these researchers and others 
established that hemophilia can manifest in the deficiency of fVIII or fIX.  In addition to 
cleaving fX, fIXa must diffuse away from cell surfaces before the coagulation process can 
reach the explosion of thrombin necessary for fibrin deposition. FXa marks the starting 
point for the common pathway and plays the largest role in thrombin generation. More 
detail on fX and its participation in the coagulation cascade are included in The Common 
Pathway and the Cell-Based Model section.  
Fibrinogen, also known as factor I, is a soluble zymogen that is cleaved by fIIa or 
thrombin. This cleavage catalyzes chemical changes within its composition such that it 
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becomes fibrin, an insoluble protein that cross-links with platelets to become the final 
clot in coagulation (20).  
Ca2+ is a divalent cation necessary for many biochemical reactions within the 
body. It has also been given the title factor IV for its participation in the coagulation 
cascade. In particular, Ca2+ is a necessary co-factor for most, if not all, coagulation 
factors to perform their respective tasks. Table II is a compilation of non-enzyme factors 
and their main function. 
Coagulation Factors:  
Cofactors  
Function 
Factor I 
Fibrinogen 
When cleaved becomes Fibrin and forms 
hemostatic plug 
Factor III 
Tissue Factor 
Receptor and co-factor that complexes with fVIIa 
Factor IV 
Ca2+ 
Divalent cation/Cofactor important in catalysis of 
proteolytic cleavage 
Factor V 
Pro-accelerin 
Cofactor and member of Prothrombinase 
Complex 
Factor VIII 
Anti-hemophilia A 
Cofactor that complexes with fIXa 
Deficiency leads to Hemophilia A 
 
 
Factor Regulation 
 Normal blood flow is maintained as long as factors in circulation are not exposed 
to endothelial components. The system is a tightly regulated culmination of positive and 
negative feedback loops. Each factor circulates in zymogen form which keeps them from 
activating each other unnecessarily, but there are other constituents in the blood as well 
as endothelial cells within vessel walls that regulate certain factors even when vessel 
injury has taken place.  For instance, thrombomodulin (TMB) is an endothelial surface 
Table II. Non-enzymatic Factors and their Functions 
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receptor and its corresponding ligand is thrombin (fIIa).  Binding of thrombin to TMB 
triggers the activation of protein C (APC) (20) APC then complexes with Protein S to 
remove fVa and fVIIIa respectively. The removal of each of these protein factors results 
in the shutdown of the clotting process by triggering the inactivation of the fVa and 
fVIIIa. Other factor regulators include tissue plasminogen activator (tPA) which cleaves 
plasminogen. Plasminogen is a zymogen involved in clot breakdown discussed in more 
detail in The Blood Coagulation Cascade section.  
The Blood Coagulation Cascade 
As discussed, the blood coagulation cascade (BCC) is activated by varying stimuli 
(2) .  An injury to the skin that pierces past the epidermal layer and reaches the 
vasculature sets the cascade in motion. Blood coagulation by definition is the cessation 
of blood loss from a damaged vessel (2). Blood coagulation is a tightly regulated series 
of events that involve the many enzymes and co-factors mentioned previously. These 
enzymes work in assembly with their respective cofactors on phospholipid membranes 
of platelets and endothelial cells to reach their full pro-coagulant complex potential (22, 
25, 26).  The early models of the BCC were established within blood vessels as a series of 
clotting factor activation events occurring in separate processes known as the extrinsic 
and intrinsic pathways. These models were established to explain the mechanisms of 
coagulation.  Figure IV is a general overview of the coagulation cascade.  
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Figure IV. General Overview of the Blood Coagulation Cascade.  
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Extrinsic Pathway  
The extrinsic pathway is ignited when disruption occurs to the endothelium on 
the outside of the vessel wall. The endothelium contains TF, a glycosylated intrinsic 
membrane protein. TF, when bound to coagulation factor VIIa, is a powerful activator of 
the extrinsic pathway. It is found all over most tissues except the lining of the circulatory 
vessels. It is not released from the endothelium without stimuli from its constituents 
such as cytokines (27). Exposure to clotting factors in the plasma results only if there is 
damage to these vessels exposing endothelial components to the blood directly. 
Because this pathway will only be initiated when the plasma-derived fVII is exposed to 
the TF which exists outside the blood vessel, this cascade is known as the extrinsic 
pathway (27, 28).   
A classic way to measure the total reaction time for the extrinsic pathway was by 
using prothrombin time (PT) experiments (20, 28, 29). Quick et al developed the 
prothrombin test in the 1930s as a means of measuring anti-coagulation (29).  At that 
time, the historical 1905 Morawitz et al study had based the coagulation process to be 
centered around 4 plasma proteins (2, 30) . Quick’s technique used patient plasma 
samples to measure the consumption of prothrombin when exposed to thromboplastin 
which is a lab reagent and protein that converts prothrombin to thrombin. 
Thromboplastin is a mixture of phospholipids and tissue factor (2). In the early 60s, 
Glover and Kuzell further developed the technique with the goal of improving anti-
coagulant therapies.  Experiments for measuring changing levels of prothrombin were 
done by the Quick one-stage plasma method using whole blood (29). Glover et al 
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employed whole blood from the finger, adjusting measurement temperatures to 37°C 
(body temperature), and altering the collection of blood with the administration of 
thromboplastin (29). 
 In addition to TF, the extrinsic pathway involves at least four other factors 
including prothrombin, Ca2+, factor X, and thrombin (27, 28). However, this model only 
works if the other components located outside the vessel are involved. This is evident in 
patients with hemophilia, because their blood could have all four elements present and 
still be unable to successfully clot.  Although the extrinsic pathway explained a great 
deal about the cascade, research has determined that it cannot work to clot the blood 
alone. Perhaps the best example of this research is the fact that TF works with FVIIa 
which circulates in the blood (31).  It also does not explain why plasma has the capability 
to clot without extrinsic components. 
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Figure V. TF/fVIIa Complex on membrane surface. Adapted from (20). 
23 
 
Intrinsic Pathway 
Classic participants in the intrinsic pathway include the following:  fV, fVIII, fIX, 
Ca2+, and fXI.  The pathway begins when thrombin converts fXI to fXIa. Then, fXIa cleaves 
fIX to make it available for attachment of fVIII. While it is now known that neither 
pathway is sufficient to seal the vessel disruption on its own, the distinction of these 
pathways remains the widely accepted model in the scientific community. As 
mentioned, fVIIIa, also known as anti-hemophilic factor, serves as the intrinsic co-factor 
for fIXa in the activation of fXa. FVIIIa catalyzes attachment of its associated components 
to the membrane surface.  The phospholipid membrane of TF-bearing cells and platelets 
acts as the arena for these activities and Ca2+ as a reaction catalyzer.  This is further 
depicted in Figure V as the area where platelet activation is controlled.  The intrinsic 
pathway is postulated to maintain its extrinsic counterpart (3, 20).  Initial techniques 
used to study the intrinsic pathway and establish it as a viable part of coagulation is to 
measure the activated partial thromboplastin time (aPTT). This test was developed in a 
similar manner to the Quick prothrombin test. Partial thromboplastin is a reagent with 
similar components to thromboplastin with the exception of TF. This process indicates 
how fast the intrinsic pathway works with respect to exhausting the factors involved. In 
other words, aPTT measures the efficiency of the intrinsic pathway. Both the extrinsic 
and intrinsic pathways occur concurrently and once complete unite into a common 
pathway.  
 
 
24 
 
The Common Pathway & the Cell-Based Model  
The common pathway is the process by which factor X catalyzes the activation of 
pro-thrombin (fII). These events that take place after pro-thrombin becomes thrombin.  
The common pathway is accepted as a true account of fibrin deposition. However, 
recent studies in blood coagulation suggest a cell-based model describes the process 
more accurately (2, 27, 28, 32).  The new model focuses greatly on more complicated 
interactions among vessel endothelium, platelets, and coagulation factors.   
Since information regarding coagulation has become more expansive, the cell-
based model suggests that coagulation occurs in 3 phases (20, 27, 32).  The first phase of 
the new cell-based model is Initiation. This step begins at the moment TF is exposed to 
the blood. As the platelets aggregate, TF forms a complex with fVII on endothelial cell 
surfaces. The TF/fVIIa autocalyzes itself to a fully activated state and then partially 
activates fIX and fX. As a form of regulation, this complex is diffused away by a special 
serine protease inhibitor called warfarin discussed in the Kunitz Inhibitors section (32). 
FIX also diffuses away to another anionic phospholipid membrane surface initiating the 
next phase of the cell-based model, Amplification. Amplification is earmarked by the use 
of thrombin (fII) as an activator for non-enzymatic factors V and XI. FXI is important for 
breaking up the complex between fVIIIa and vWF. This step is critical as fVIIIa is a 
necessary co-factor for fIX. This step is carried out on the surfaces of the platelets that 
were initially exposed to TF. 
The initiation and amplification phases are the priming phases as every factor 
involved is not fully activated. During the final phase, every factor becomes activated. 
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The third phase is called Propagation. FVIIIa/fIXa forms a complex with fXa on platelet 
membranes (called the Tenase Complex) partially activating it and prompting it to then 
couple with fVa (20). The result is a burst of thrombin. Thrombin generation at high 
levels cleaves large amounts of fibrinogen into fibrin. Fibrin monomers (or subunits) 
clump together with platelets and form a “soft” clot. FXIIIa , also known as the enzyme 
transglutaminase, seals this soft clot by cross-linking the platelet/fibrin mix. Once this 
cross-linking is complete, the hard clot is formed. 
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Figure VI. Initiation, Propagation, & Amplification Phases of the Cell-Based Coagulation 
Model. Adapted from (20). 
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Breakdown of the clot is an important step in coagulation as well as it marks the 
stopping point of the clotting cascade. Fibrinolysis occurs when the clot is disintegrated 
after the vessel disruption is rectified. Plasminogen is a zymogen that is activated by tPA 
to become plasmin. Tissue plasminogen activator (tPA) and single-chain urokinase 
plasminogen activator (scuPA) are enzymes necessary to activate plasminogen (20). 
Plasmin will then cleave fibrin and trigger clot destruction. This step is another form of 
regulation mechanisms for the maintenance of hemostasis. Protein C and protein S are 
both participants in the proteolytic deactivation of factors Va and VIIIa. This process will 
be further explained in the Cascade Regulation section. Plasminogen activator inhibitor-
1 (PAI-1) and a2-antiplasmin are proteins that serve as negative regulators of this 
process. 
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Figure VII. Factor VIIa—catalytic head, 2 EGF 
Domains, and Gla domain. Adapted from (116) and PDB 
ID: 1KLJ. 
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Factor Structure 
As described, there are over a dozen clotting factors circulating through the 
blood. These factors each play a significant role in coagulation. Many of them share a 
structure that contains a catalytic head (similar to trypsin), two epidermal growth 
factor-like domains, and a Gla domain.                                   
Although they are similar in structure, they are distinct in their degree of 
specificity for each of their respective co-factors and substrates. In order to understand 
our purpose in examining fXa, it is important to examine some of the other coagulation 
factors and their particular role in the BCC cascade. The 1940s marked an era in which 
many researchers began to focus more closely on the coagulation process (reviewed in 
(27)). Clotting factors were assigned numbers that correspond with their sequence of 
discovery rather than their point of interaction within the BCC (23, 33). Factor Va is 
activated by proteolytic cleavage. As seen in Figure III, Factor Va serves as co-factor for 
fX. It is very homologous with fVIIIa, which interacts with the anionic phospholipid 
surface and requires proteolytic cleavage as well (34). Upon complex formation with fVa 
and prothrombin (also known as the prothrombinase complex) on negatively charged 
phospholipid membranes, fXa converts prothrombin to thrombin in the final stages of 
the coagulation cascade (15, 22, 35-38). Although fX is capable of some activity prior to 
the assembly of the prothrombinase complex, that capability is minimal. This 
prothrombinase complex enhances the catalytic efficiency of fX greatly because it 
improves the Km (Michaelis’ constant) and Kcat of the substrate activation reaction (38).  
Km improvement is credited to the binding of the Gla domain and prothrombin on the 
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membrane surface. Yang et al conducted a study regarding fVa and its contribution to 
the improvement of Kcat. Their findings indicated that among its other tasks fVa causes 
conformational changes of the Na+ binding loop of fX.  Researchers constructed fX 
mutants with critical residues Glu-217, Lys-224, and Arg-221a replaced with an alanine 
to study the catalytic function of fX as well as its interactions with the metal ion Na+. 
After replacing these residues, Na+ interaction was markedly impaired. However, in the 
presence of fVa, the defect in fX catalytic efficiency appeared to be improved.  By 
binding both fX and prothrombin, fVa stabilizes the enzyme-substrate complex and 
provides ideal docking capabilities for other necessary participants (38). Na+ plays an 
important modulatory role in the structural and chemical functioning of many of the 
serine proteases involved in coagulation (39).  Figure III is a depiction of how fVa 
complexes with fX to activate it.  
 
Cascade Regulation  
Regulation of the BCC is of extreme importance that involves a delicate balance 
of all the components described here. This process is that of a negative and positive 
feedback loop which works to seal any disruption and maintain blood fluidity. Changes 
are seen in blood fluidity as a result of such external or internal stimuli problems as 
vessel injury, or increases in blood pressure, or fluctuations in hormones (40, 41). These 
increases in blood pressure can occur as a result of cholesterol buildup or chemical 
imbalances like sodium or coagulation factors. Table IV is a compiled list of known 
cascade regulators.   
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Coagulation Regulation 
 
Function 
Thrombomodulin 
(TMB) 
Receptor, when thrombin is attached coagulation activity 
is suppressed 
Protein C 
(APC) 
Serine protease activated by TMB/thrombin complex ; 
APC/APS complex dissolves fVa and fVIIIa 
Protein S 
(APS) 
Co-factor for Protein C 
See above 
Tissue Plasminogen Activator 
(tPA) 
 
Activates plasminogen for hard clot breakdown 
 
Single-chain Urokinase Plasminogen 
Activator (scuPA) 
Plasminogen Cleaves cross-linking for hard clot breakdown 
 
Protein C and protein S play important roles in regulation when activated as well. 
The APC/APS complex is responsible for the dissolution of fVa and fVIIIa respectively (40). 
It is triggered by the attachment of thrombin to one of its receptors called 
thrombomodulin (TMB). FVa and fVIIIa function have been described and are critical to 
the continuation of the clotting cascade. Without their presence, blood clotting activity 
is suppressed.  
 
Traditional Therapies & Treatments 
When the regulation processes of blood described previously are not controlled 
properly, the result presents in a number of issues and diseases. In addition to 
physiological regulation, diet and genetics both play an integral role in blood regulation. 
Although this paper will go into detail on a few of the diseases associated, the focus of 
Table III. Cascade Regulation 
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poor regulation of the process is narrowed to genetic de-regulation which can lead to 
issues including hemophilia or von Willebrand disease.   
Hemophilia 
Hemophilia is a rare, genetic bleeding disorder in which blood does not clot 
properly (42). It is an X-linked recessive disorder caused by a functional deficiency in 
fVIIIa or fIXa. A deficiency in fVIIIa results in Hemophilia A while deficiency in factor IX 
leads to Hemophilia B (24, 43, 44) .  Each of these factors is a member of the intrinsic 
pathway necessary for the activation of fX. Deficiencies in either or both result in an 
abnormal or non-existent clot formation (24, 44) . Patients suffering from this disease 
usually exhibit excessive bleeding post-injury no matter how minor in many places 
including the skin, brain, or joints (43, 44). One of the most popular courses of 
treatment is replacement therapy (42).  The clotting factors for which the patient is 
deficient are replaced in the blood by infusion. Though these factors are harvested in 
donated blood and have a relatively low ability to incite an immune response in foreign 
blood, complications can occur including antibody formation against foreign clotting 
factors. Immune responses can destroy them before they have a chance to work (15, 45) 
. Clotting factors circulate in the blood and are therefore susceptible to being exposed 
to other organisms circulating in the blood including viruses and consequently can be 
affected by them. While these complications are serious, they are rare as the screening 
process for donated blood is rigorous and thorough (4, 25). Other treatments are 
available for hemophiliacs including but are not limited to gene therapy as well as anti-
fibrinolytic medicines.  
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Factor Va Leiden Mutation 
The Factor Va Leiden mutation is another example of a coagulation disorder. 
Patients inherit the FVL allele which contains a missense mutation. A single G nucleotide 
is replaced with an A, which alters its functioning (46, 47). The mutation alters the 
arginine at the 506 position and replaces it with a glutamine. This single residue 
polymorphism causes fVa resistance to the degradation that takes place during the APC 
pathway mediated by thrombomodulin. The Arg-506 is one of the three cleavage sites 
protein C uses to degrade fVa during the cessation of the cascade.  Ultimately, fVa 
becomes resistant to degradation and also gains the ability to perpetuate the cascade. 
FVL can cause a number of anomalies including venous thromboembolism, deep vein 
thrombosis, pre-eclampsia, pulmonary embolism, and miscarriage. Van Mens et al 
reported a high prevalence of FVL at 5% in Caucasians (46). The review study these 
researchers completed was based on understanding the evolution of FVL as well as its 
advantages and disadvantages. Disadvantages were already mentioned. However, some 
of the advantages reported by van Mens included decreases in intrapartum blood loss in 
affected females giving birth, decreased menstrual blood loss, patient survival of severe 
sepsis, and fecundity (46).  
 
Anti-coagulants 
This study is focused on the inhibition of fXa, which essentially inhibits the 
coagulation cascade. Therefore, it is important to note how anti-coagulants work. Ticks 
and leeches naturally produce these anti-coagulation agents, which have powerful 
34 
 
mechanisms to prevent blood from clotting. They do so as a method of feeding on the 
blood of its host. Physicians often use anti-coagulants during surgical procedures to 
prevent the blood from clotting as a result of an incision to the body or other induced 
trauma to the circulatory vessels. Also, they are used as treatments for patients plagued 
with thrombotic disorders such as atherosclerosis or prone to strokes (43).  
Among some of the most commonly used anti-coagulants are coumarins (48). 
These agents work by blocking the activity of vitamin K. Warfarin, a vitamin-K 
antagonist, is the most used anti-coagulant in medicine to date (20). Warfarin is a 
member of the coumarin family. It is such a great anti-coagulant that it is used as 
pesticide, more specifically as a rat poison. As previously stated, serine proteases 
including fIX and fX are vitamin-K dependent and susceptible to inhibition by warfarin. 
Warfarin decreases γ-carboxylation of Gla residues in fX and other coagulation factors 
by blocking the mechanism of the enzyme, vitamin K reductase, needed to replenish 
active vitamin K (20). Vitamin K reductase regenerates the vitamin in hepatocytes. 
Without a steady stream of active vitamin K, γ-carboxylation is blocked preventing 
coagulation factors from docking on membrane surfaces. While it is the most frequently 
used clot inhibitor, there are a few issues associated with its effectiveness. For example, 
its effects take up to 3 days to act. Additionally, this substance has a lack of specificity in 
regard to clotting factors. Its role as a vitamin-K antagonist makes warfarin difficult to 
use because of its varying dose requirements and narrow therapeutic range. Its high risk 
for serious bleeds especially is what makes proper dosing very difficult. It has been used 
to treat deep vein thrombosis and atrial defibrillation (49).  For this reason, it is often 
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distributed alongside a serine protease inhibitor known as heparin. Further discussion 
on the significance of heparin can be found in a sub-section below. Though using these 
anticoagulants is useful, one drawback is that both of them lack specificity—they 
decrease the activity of every component requiring vitamin K.  
The Importance of Factor X 
Factor X is a very important part of the blood coagulation cascade because its 
activation is primarily responsible for thrombin generation. For the purposes of this 
study, a particular focus is being placed on fX. As discussed, thrombin is necessary for 
the conversion of fibrinogen to fibrin. It is activated by the factor VIII and IX co-factor 
complex.  
Proteolytic activation within the intrinsic and extrinsic pathways causes 
conformational changes in and around the active sites of fX molecules to render the 
entire complex as a pro-coagulant. FX cleavage between Arg15 and Ile16 by the fVIIIa,/ fIXa 
complex is important in its activation. This site near the N-terminus of the fX substrate 
forms a salt bridge at the catalytic head (27, 33, 50). FXa has both a light chain and a 
heavy chain held together by a single disulfide bond. The light chain contains the N-
terminal glutamate domain (called the Gla domain) conserved across many coagulation 
factors in addition to two epidermal growth factor-like domains. This Gla domain 
contains 11 γ-carboxyglutamic acid residues which mediate electrostatic binding to the 
negatively charged phospholipid membrane in the presence of divalent calcium ions. 
The heavy chain contains its trypsin-like serine protease domain. At the point of 
activation, the BCC has left the extrinsic and intrinsic pathways respectively and entered 
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the common pathway. The common pathway is where pro-thrombin is converted 
through a series of steps to thrombin. Pro-thrombin contains 10 Gla residues. The 
prothrombinase complex includes fXa, fVa, phospholipids, and Ca2+. Refer to Figure III for 
a depiction of the prothrombinase complex. 
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Figure VIII. General overview of fX Activation 
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fXa Topography 
While the shape and genetic organization of fXa was mentioned briefly 
throughout this report, it is important to go into further detail as it pertains to this 
study. Fluorescent Resonance Energy Transfer (FRET) has been used for many years to 
study biochemical agents on a molecular level such as fX (51-53) . FRET is defined in 
short as a technique used to measure the interaction between two different molecules 
(53, 54) . These molecules are labeled with fluorophores which are also known as either 
a donor or an acceptor. The donor is said to be the molecule in an excited state and the 
acceptor is the molecule nearest to it. It was first discovered by Fӧrster et al (55) .   
There are different types of FRET including but not limited to emission measurement or 
acceptor photo-bleaching. In either case, FRET techniques monitor whether or not the 
donor molecule emitted energy and whether the acceptor molecule receives it (53).  
Qureshi et al measured distances within fXa using FRET,  between donor fluorescein dye 
in the active sites of FI-FPR-inhibited fXa and its N-terminal EGF deletion mutant, fXa-
desEGF1 (56). FI-FPR stands for fluorescein-D-Phe-Pro-Arg-chloromethane.  The Qureshi 
results indicated that an EGF spacer functions to hold the fXa active site above 
phospholipid membrane surfaces. Not only this, this study found that fVa alters this 
orientation in an unknown but significant conformation (56). This information is integral 
to understanding more about fXa itself as well as its topography.  
FXa inhibition can be measured via enzymatic kinetics as seen in (57-60).  
Competitive inhibition is measured using solution-based chromogenic substrate 
competition assays. Chromogenic substrates are colorless chemical compounds which 
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react within enzymatic reactions by generating a colored product (61, 62) .  This product 
is usually generated because the substrate has been cleaved during the reaction. The 
product of the chromogenic substrate is known based on which substrate is used. The 
absorbance of the product is noted and is a point of reference during data analysis.  This 
technique has been used many times to characterize protease functioning (61, 62). By 
measuring the rate of substrate hydrolysis (i.e. consumption). Additionally, Budzynski et 
al. explains that chromogenic substrates have also been very useful in determining the 
zymogen form of these proteases as well (62). With the appropriate activator, 
controlled chromogenic assays can be used to monitor activated enzyme amount to the 
inactivated enzymes in the area.  
By measuring the rates of chromogenic substrate cleavage, other factors 
involved in these mathematical calculations include inhibitor concentration, Michaelis’ 
constant for substrate usage (Km), steady-rate velocity without the inhibitor (Ki), steady 
rate velocity with the inhibitor, experimental substrate concentration, and the 
asymptote or remaining saturating inhibitor present (58). The Michaelis Menten 
constant represents the substrate concentration at which 50% of maximal enzymatic 
activity in an experiment is measured. The Ki represents the point at which 50% of the 
enzymatic activity is inhibited. To calculate this one would measure inhibition of the 
desired activity takes place until 100% inhibition is reached. Then, calculate the slope of 
each experiment and use that information to determine the Ki.  The slopes of these 
experiments will be useful to plot a linear graph which can indicate the relationship of 
the enzymatic inhibition over time. The enzymatic inhibition time is directly linked in 
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determining fX topography as it relates to the distance at which fX can be inhibited 
using this construct and others constructed after it. 
 Studies report that the enhancement in the catalytic activity of fXa in the 
prothrombinase complex appears to arise from two orders of magnitude improvement 
in the Km or the concentration of substrate to activate prothrombin. This is because of 
the Ca2+ dependent interactions between the protease/substrate complex via their Gla 
domains on the same negatively charged membrane surfaces. There are a total of 5 
orders of magnitude increases. Thus, the remaining three orders of magnitude 
improvement in the catalytic efficiency of fXa is attributed to the co-factor function of 
fVa which improves the kcat (or catalytic rate) of the activation reaction by interacting 
with the protease and/or the substrate on the membrane surface (56).  
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Figure IX. A ribbon diagram of fX. Adapted 
from (115) and PDB ID: 2BOK. 
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FX Regulation 
 Serpins 
While regulation of coagulation factors was discussed briefly already, it is 
necessary to understand the level of importance in relation to fX specifically. Clotting 
factors are inhibited in a number of ways. Serpins are a group of serine protease 
inhibitors, hence the breakdown of the word ser for serine, p for proteases, and ins for 
inhibitors. They are produced mainly in the liver and comprise almost 10% of plasma 
proteins. Similarly to the clotting factors, any number of serpins float freely in the blood 
as needed to control hemostasis. KPIs or Kunitz-type protease inhibitors are classified as 
serpins. This group includes anti-thrombin III (ATIII) and anti-trypsin as well. ATIII is a 
protease inhibitor produced by the liver which targets serine proteases including fIXa, 
fXa, and thrombin. ATIII is a small glycoprotein that contains an arginine within its active 
center that reacts irreversibly with a catalytic-site serine in thrombin; this creates an 
inactive complex (63) .  
Heparin 
Heparin, a known anti-coagulant polymer, potentiates ATIII activity (64-69) . A 
more specific definition of heparin would be that it is a sulfated polysaccharide. Because 
heparin works well and is very efficient at completing its task, it is often coupled with 
warfarin in clinical settings. Surgeons often employ it to decrease incidence of clotting 
during procedures. Enoxaparin is a pentasaccharide form of heparin (70). It is classified 
as a low molecular weight heparin used to measure its own potentiation characteristics 
as compared with heparin. One of the benefits of this particular heparin is it has 
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specificity for fX. Heparin and its derivatives is a powerful anti-coagulant that works 
specifically by binding to a basic amino group in the ATIII active site such as arginine. 
When complexed with ATIII, the inactivation rate of thrombin increases significantly 
(71). Therefore, thrombin remains deactivated for a longer period of time than under 
normal circumstances, which leads to a decrease in coagulation.  Once thrombin is 
bound to fibrin it is resistant to the inactivating capabilities of ATIII or the ATIII/heparin 
complex. Thus, ATIII can directly or indirectly inhibit fXa. ATIII blocks thrombin via 
conformational change from forming a clot in the blood. In addition to its interactions 
with ATIII, heparin serves as a regulation mechanism for fX vide infra. Because warfarin 
can take as long as 72 hours to act, heparin is often used to accompany it as an 
additional treatment. It is said to have the highest negative charge of any natural 
polymer in the system and is very closely related to another polymer known as heparan 
sulfate located on epithelial surfaces of blood vessels because it contains structural 
similarities including repeating disaccharide units.  
As discussed, heparin has many benefits, but it has some negative characteristics 
as well. Not only does high molecular weight heparin lack specificity, it can also cause 
clinical issues such as heparin-induced thrombocytopenia (HIT). HIT is characterized by 
excessive clotting within the patient along with a dramatic decrease in circulating 
platelets (i.e. thrombocytopenia) associated with the presence of excess heparin (20). 
Heparin has the ability to bind platelet factor 4 (PF4) which triggers an immune 
response within the body. This immune response causes the body to classify its own 
cells as foreign resulting in an attempt to remove them. To reverse these effects, 
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doctors remove heparin from the blood by filtration or allowing the body to do so via 
metabolic mechanisms and use another anti-coagulant.  
Many studies including Deadmond et al found heparin to be a powerful 
modulator of activity of coagulation factors as well. In an effort to establish the 
relationship between fIXa and heparin, the Deadmond study used slow-binding kinetics 
and serine protease inhibitors including basic pancreatic trypsin inhibitor (BPTI), tissue 
factor pathway inhibitor, and nexin to determine how heparin is increasing fIXa 
reactivity in their presence. Each of these substances are serpins capable of inhibiting a 
specific portion of the coagulation process. BPTI targets fXa, TFPI targets the extrinsic 
pathway via tissue factor and factor VIIa. Nexin targets thrombin and has been used in 
recent studies to be useful with regard to central nervous system circulation (72). 
Results indicated that heparin modulates a specific loop at active site 99 within fIXa that 
allows for better inhibition by BPTI (57).  
The Role of Kunitz Inhibitors 
The initial discovery of Kunitz-type protease inhibitors (KPI) described them as 
globular soybean proteins, which act to inhibit trypsin much like the ones that regulate 
fX. Since then, it has been established that not all KPIs are soybean proteins.  Some are 
human proteins; thus, KPIs are conserved across phyla structurally and functionally. KPIs 
operate to inhibit a number of processes within the body including digestion, blood 
coagulation, and inflammation.  In digestion, they serve to stop or slow trypsin and 
chymotrypsin (48). Their influence on chymotrypsin is significantly less than its actions 
on trypsin. In inflammation, they work to decrease the activity of the inflammatory 
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enzyme, elastase allosterically (73). In blood coagulation, KPIs inhibit various factors 
such as kallikrein and fXa (74).  
Studies published by M. Kunitz in 1946 established the chemical properties of 
these inhibitors and were therefore named for him (48, 74). KPIs were characterized as 
stable globular proteins with estimated molecular weights of up to 24,000 Daltons (Da) 
and the ability to inhibit the actions of trypsin.  It was also reported that the inhibitor is 
active only in its native or unaltered state (48).  The interactions of these inhibitors in 
combination with their respective substrates take place on the lipid membrane to 
obtain full enzymatic activity. There have been so many types of KPIs isolated and 
reported since that time that it is commonly referred to as a superfamily. Some 
examples of KPIs include basic pancreatic trypsin inhibitor, substilisin inhibitors, and 
anti-thrombin III.  
 
Inhibitor Structure 
The molecular structure of these inhibitors contains varying combinations of ≤ 
200 amino acid residues. Many KPIs contain conserved regions of disulfide bonds 
consisting of four cysteine residues within a single or double polypeptide chain (74) . 
Two distinct characteristics in the KPI structure are its secondary and tertiary make-up. 
The secondary KPI structure is described as devoid of an α-helix; rather, it has 12 anti-
parallel β strands connected together via long loops instead. Thus, the tertiary structure 
is that of tri-folds of these β strands. The active site on these inhibitors is usually located 
near the lysine or arginine residue within the structure.  
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Basic Pancreatic Trypsin Inhibitor 
Basic pancreatic trypsin inhibitor (BPTI) is a kunitz-protein inhibitor which is of 
particular interest in this study. BPTI is approximately 58 amino acid residues in length. 
It is a single-chain polypeptide, which has a molecular weight of about 6,512 Da and a 
size of 30Å (73, 75). It is string-like in structure and folds upon itself twice and is held 
together by 3 disulfide bonds.  It is one of the smallest and simplest of the globular 
proteins (76).  
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Figure X. BPTI structure including the Lys15 region, N-terminus, C-terminus, 
and three disulfide bonds denoted by the black double arrows.  Adapted 
from (74) and PDB ID: 9PTI. 
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It functions to inhibit a broad spectrum of digestive enzymes. It works in 
particular to suppress the breakdown of proteins into its building blocks (i.e. amino 
acids) by inhibiting trypsin produced by the bovine pancreas (73) . This serves to 
carefully control trypsin and assure that important proteins are not degraded arbitrarily. 
BPTI has been heavily studied which means that its structure and mechanisms are well-
characterized.  It is stabilized by a small hydrophobic core formed by an internal packing 
of non-polar amino acid side chains. Its 3 disulfide bonds add further stability to the 
molecule.  
Understanding how BPTI works has been extremely instrumental in understand 
protein-protein interaction and molecular recognition on a much clearer level. This 
interaction and the information it has provided prompted this study regarding the 
actions of fX more closely. The normal inhibition rate for fXa with non-native BPTI ranges 
depending on the system and the co-factors involved and works well as a tool for 
comparative purposes. However, previous inhibition studies have suggested that it takes 
place in a two-step inhibition reaction involving a reversible binding step with a Ki of 
about 1.13µm/s as well as an irreversible alkylation step with a rate of ki of about 
0.65µm/s. This information is based upon fXa interaction with fVa and BPTI in solution or 
on membranes (34).  
 
Research Design 
Current Information and Fluorescence Studies 
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Fluorescence studies indicate that distance of closest approach to the membrane 
of the active site of several of various clotting proteases is highly important. In other 
words, the topology of these pro-coagulant complexes is an important concept to grasp 
especially because it could provide insight into their specificities (see Future Aims for 
more information). However, an understanding of topology and reactivity of these 
complexes is limited and, therefore, a critical gap that needs to be filled.  In multiple 
instances, substrate binding has been demonstrated to alter the distance of closest 
approach. X-ray crystallography shows the distance of closest approach to be similar to 
the length of these coagulation proteins. Thus, these enzymes (i.e. clotting factors) 
appear to orient themselves in a vertical manner on the membrane surface with little or 
no bending. This inference has not, however, been confirmed using fluorescence 
resonance energy transfer-based studies on actual distance for optimal pro-coagulant 
activity. It does not provide any information on the elasticity (ability to change) of these 
pro-coagulant complexes or its ability to stretch in the vertical direction. Specifically, we 
believe that the fXa pro-coagulant complex may achieve a maximally-effective pro-
coagulant capacity when held at a specific orientation above the phospholipid 
membrane in its cofactor/substrate complex.  Ultimately, this study will examine and 
compare the range of reactive heights of the fXa alone and fXa/fVa pro-coagulant 
complex above the membrane surface by using an inhibitor substrate (recombinant 
BPTI with a linker) that is anchored at specific heights above the phospholipid surface.  
The length of the anchor, which gives maximal inhibition will indicate the distance of the 
maximally reactive catalytic site above the membrane. 
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Previous Studies and Study Goals 
The goal of this study is to gain understanding as to the topography of fXa in the 
presence of BPTI. The following are studies done by other laboratories which provide 
insight regarding the reactivities of the pro-coagulant complex using proven methods 
planned for use in this project.  
Proof of concept using lipid-tethered inhibitors.  
 The viability of anchoring Kunitz-based inhibitors to lipid membranes for analysis 
was tested using Surface Plasmon Resonance (SPR) (77). The SPR experiments measure 
the binding of any two molecular partners in real-time without the requirement of 
labels via changes in the refractive index (57). In particular, researchers generated a 
phosphatidylcholine (PC) lipid monolayer containing nickel-chelating head groups (used 
for neutralization purposes) and a 6-histidine tagged BPTI was successfully attached. 
Soluble proteases were then flowed over the surface, and their capture by the inhibitor 
was monitored in real time. The results of these studies indicated that BPTI is capable of 
binding target proteases under these conditions (78). Though lipid-tethered KPIs can 
potentially retain their function with these proteases, functioning is optimal when the 
proteases are in a soluble state. In addition to those results, the on-rates of binding 
were much lower than expected based on solution-phase studies done prior (79).  
Negative steric effects derived from holding the KPI close to the lipid surface may be the 
explanation for this phenomenon as well as preference of enzymes for maintaining a 
vertical orientation on the membrane.  Results from previous studies such as this 
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indicate that slow binding is predicted to increase substantially when elevated from the 
membrane.  
 
Expression and purification of an active inhibitor 
  BPTI and other known protease inhibitors were directionally cloned into pET11a 
DNA system using techniques outlined in Anderer et al (80). Recombinant inhibitor DNA 
was confirmed using sequencing. Next, each was expressed as inclusion bodies in 
BL21(DE3), an expression strain of Escherichia coli (81-83). The methods used in the 
Deadmond study are outlined here as a template for use in this study. These cells were 
grown in terrific broth (TB) and 50 µg/ml Carbenicillin at 37°C until log phase was 
reached. Carbenicillin is a common substitute for ampicillin if unavailable or the need 
for a more stable antibiotic is necessary (84). Terrific broth is a mixture of peptone (a 
soluble protein), yeast extract, and glycerol which is rich in nutrients for bacterial 
growth (85).  After log phase was reached, 0.5 mM isopropyl-β-D-1-
thiogalactopyranoside (IPTG) was used to induce protein expression over a 4-hour 
incubation period at 37°C. Using techniques as outlined by Steinle et al, the inclusion 
bodies were collected and solubilized (86). Next, the solution was clarified using 
centrifugation. Then, a protein preparation of the inhibitor was exposed to oxidative 
refolding.  Oxidative refolding is a process by which disulfide bonds are forged in the 
desired protein. Techniques as outlined by Clark et al were used. The 6-hour process 
was allowed to take place with a coordinated stirring step until the protein was properly 
folded. Exhaustive dialysis of the folded protein into buffer fluid was prepared for ion-
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exchange chromatography. Column chromatography was used for protein expression 
and purification purposes. Columns designed specifically for BPTI inhibitor affinity were 
used to elute the protein.  First, a column was designed to contain bound trypsin. It was 
used followed by a 0-1M NaCl gradient wash. Then, the inhibitor was eluted by 
deactivating bound trypsin with a very low pH elution buffer with Ca2+. Then, the eluate 
(expected inhibitor) was neutralized immediately using 2M Tris buffer. SDS-PAGE was 
used to determine the protein concentration at 95% purification.  Factors involved in 
the clotting cascade including fIXa and fXa were activated using Russell’s Viper Venom 
(RVV) (87, 88). RVV activates these factors as they would if exposed to extrinsic 
components.  Then, standard single-stage clotting assays with a coagulometer were 
performed. The reactive sites of recombinant BPTI were then titrated. This method 
described the inhibitory activity of the inhibitory protein (79).  FIXa enzymes were 
incubated in 150 µM biotin-EGR-ck in tricine, NaCl, CaCl2, and ethylene glycol.  The 
active sites of these biotin-EGR-fIXa enzymes were collected as described by Mann et al. 
The enzyme-linked immunosorbent assay was used to quantify these enzymes with goat 
anti-fIX polyclonal capture antibody as well as alkaline phosphatase-conjugated 
Streptavidin. Streptavidin is a commercially available protein with a very high affinity for 
biotin. Once both the reactive sites of the BPTI inhibitor and the active sites of the fIXa 
were collected, equilibrium enzyme inhibition assays were completed.  Specifically, 
equilibrium of fIXa amidolytic activity (cleavage of an amide) was measured using 
reversible competitive inhibition. The equation for calculating the equilibrium constant 
or Kieq was as follows: 
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vs = vO Kieq (1 + S /Km) 
                                                                  1 + Kieq (1 + S/ Km) 
 
Vo describes the steady state rate obtained without inhibitor present. Vs represents the 
steady state rate at each concentration of the inhibitor. S represents the experimental 
substrate concentration, and the Km is Michaelis’ constant for substrate hydrolysis. The 
equilibrium rates were used to determine the activity rates based on the slow-binding 
enzyme inhibition assays that followed. Kinetic parameters for these assays were 
obtained from Morrison et al and Copeland et al (89, 90) . The conditions of these 
experiments were very similar to that of the equilibrium assays except that the fIXa 
enzymes were incubated with or without enoxaparin (low molecular weight heparin 
mentioned previously) before they were used in the reaction mixture. Varied 
concentrations of the inhibitor were co-incubated with a pre-determined quantity of 
trypsin. At equilibrium, a chromogenic substrate was added to measure absorbance at 
405 nm for 30 minutes. These measurements indicated substrate hydrolysis over time. 
The results were tallied from the lowered rates of color and compared to one another to 
generate a curve used to calculate the amount of viable inhibitor. The lowered rates 
indicated trypsin inhibition.  A computer software called KINEMAX was used to generate 
data curves for the analysis of slow inhibition.  The series of equations used in this study 
allowed for the calculation of reactivity using variables including the time, initial 
absorbance, initial rate of substrate hydrolysis, and so on. This information allowed 
researchers to generate data plots, use the slopes of each kobs calculated, and measure 
how close kobs is to the equilibrium data.  
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Construction of a base vector  
 LAGC Consensus Sequence 
An expression plasmid was constructed to include the BPTI inhibitor as well as a 
bacterial lipophilic tag located after the consensus sequence at the C-terminal called 
LAGC. This is the common sequence for lipid-anchored bacterial proteins named for 
[LVI][ASTVI][GAS]C amino acid sequences (83). Biological systems including 
Staphylococcus aureus and E. coli bacteria have developed this machinery as a means of 
survival. Nutrient uptake, signal transduction, growth, and development are all 
processes dependent upon many membrane-bound proteins (83). Additionally, ELISA or 
enzyme-linked immunosorbent assays and other biosensors use membrane-bound 
proteins in order to successfully complete tasks such as diagnostics and substance 
identification.  The Kamalakkannan study demonstrated that cloning a target gene 
sequence behind the LAGC sequence led to lipid-anchored expression of otherwise 
normally secreted proteins (83). These researchers used two respective strategies to 
genetically alter a non-lipoprotein into a functional lipoprotein. This motif is recognized 
by bacterial machinery, more particularly an enzyme called diacylglyceryl transferase. 
This enzyme modifies the moiety sequence in a two-step reaction leading to the 
cleavage between the Gly and Cys residues. Then, there is an addition of an N-acyl, s-
diacylglyceryl moiety to the N-terminal Cys (91-93) . The moiety is highly hydrophobic 
and incorporates in the lipid membrane, and its following peptide sequence is expressed 
in the periplasmic space. Figure XI is a depiction of the chemical structure of this moiety.  
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Figure XI. N-acyl, s-diacylglyceryl moiety group at the N-terminal Cys group 
associated with the LAGC consensus sequence. PR1 and 3 are the palmitoyl residues. PR2 
may be a palmitoyl or oleayl residue. Adapted from (83).   
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Inhibitor Ruler Proof-of-Principle  
The Deadmond et al. plasmid developed was modeled exactly as the 
Kamalakkanan vector with a pET11a backbone modified to contain a ribosome binding 
site, a 10 base-pair spacer, the sequence coding for the 23 amino acid leader sequence, 
and followed by sequences coding for Leu, Ala, Gly, and Cys. The leader sequence is of 
significant importance as it was taken from the apyrase gene (83).  Shigella apyrase is a 
model protein used in the Kamalakkanan study for a number of reasons. It is easy-to-use 
and assists in the release of phosphate groups from organic and inorganic 
pyrophosphates (93). It guides the protein into the periplasmic space, which supplies 
the oxidative environment needed for the inhibitor to spontaneously fold.  Finally, the 
construct contained a restriction enzyme site along with the sequence for BPTI. 
Verification to confirm this construct was built optimally was done via sequencing. 
Relipidation of recombinant proteins  
 Recombinant BPTI with the LAGC-tag was relipidated with 100% 
phosphatidylcholine lipid vesicles. The relipidation process is completed by incubating 
the recombinant DNA in the presence of phosphatidlycholine as well as detergent 
composed of phospholipids and glycopyranoside. It is necessary in order to ensure that 
the recombinant proteins will work as expected to that of the body. More specifically, in 
experiments performed on prothrombotic surfaces attempting to mimic in vivo injuries, 
it is necessary that modified factors be relipidated for attachment to surface bound 
collagen fibers as seen in (94). After that, the mixture is combined with a solution of 
chloroform and methanol and dried onto a thin film in liquid nitrogen. It is then placed 
57 
 
under a vacuum for a minimum of 2 hours to remove any undissolved organic solvents. 
Next, the film is dissolved in a mixture of glycopyranoside, Tris-HCl, and apoprotein. 
Upon incubation for at least an hour, the detergent is removed by dialysis. The 
relipidated protein is treated for up to 2 days with buffer until it is ready for use. Protein 
confirmation and concentration was verified by gel filtration chromatography. In this 
experiment, a large portion of recombinant BPTI co-eluted with a lipid fraction. 
Whereas, native (non-lipid-anchored) BPTI elution profiles eluted after the lipid fraction 
using similar conditions.  
EA3K Linker Sequence 
 The EA3K linker sequence is the portion of the recombinant plasmid that serves 
as the molecular ruler. Its sequence codes for a string of repeated amino acid residues 
that read (using single letter coding) as E-A-A-A-K. They are rigid and helical in structure. 
The structure is important as they allow for better control regarding the length in which 
the inhibitor will be raised off of the membrane surface. Each linker is approximately 
10Å in length. The structural height of the linker is about 7.5Å as they attach to one 
another in a unique diagonal manner (refer to Figure XII).  Arai et al used the EA3K linker 
to enhance protein fusion experiments (95).  The linkers were an important tool in 
bridging α and β domains between each protein to create a fully functional chimeric 
protein. The oligonucleotide sequence designed for this study contains ten of these 
linkers. This means that the recombinant BPTI would be raised 75Å from the membrane 
surface.  
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In addition to the E-A-A-A-K repeats, the sequence also contains a G4S flexible 
linker. This linker as suggested by its name codes for peptide sequence, G-G-G-G-S. One 
important reason these linkers are expected to work well in the recombinant DNA is 
because they have been used successfully in the past and do not typically alter protein 
activity. Su et al used this linker to allow for recombinant erythropoietin designed for 
the study to enable the moiety of the protein the ability to form its native three-
dimensional structure properly as well as function in its environment as naturally as 
possible (96). Its hydrophilic and neutral chemical composition allows these processes to 
take place. Ultimately, the G4S linker provides the protein with the ability to float in a 
flexible manner as it would in the environment and increase its chances of attachment 
to serine proteases in the area (97).  
  
59 
 
 
 
 
 
  
Figure XII. EA3K Linker Structure. This is a theoretical depiction of what the EA3K linker 
sequence resembles. The length is demarcated here as well. 
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Overall Study Aim 
This study proposes that as the inhibitor is raised from the membrane to an 
optimal level binding is increased; therefore, its functioning is improved. In an attempt 
to confirm this hypothesis the following steps were taken. 
 
Specific Aims: 
Specific Aim 1: Construct a plasmid using a pET11d backbone containing the LAGC and 
EA3K sequences respectively 
Preliminary results obtained from Neuenschwander et al. demonstrate proof-of-
principle for generation of lipid-anchored BPTI (57, 79). The construct will generate 
sequences encoding a bacterial lipid-anchor consensus site separated by a set number 
of linker sequences. More specifically, a segment coding for an LAGC leader sequence 
and EA3K linker sequences will be directionally cloned into pET11d E. coli DNA. Below is 
a simplified image of what the generated construct will look like:  
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FigureXIII. Projected graphic map of p-LAGC-EAK10-BPTI. LAGC sequence is denoted in the 
color orange, EA3K in green, and BPTI in yellow.  Restriction enzyme sites are noted in the black outlined 
blue boxes. The ampicillin promoter (Amp prom) and repressor (AmpR) region is noted. The lacI region 
is a part of the pET11d is a mutated promoter region that controls the lac operon. ColE region of this 
bacterial plasmid that aids in the survival of the plasmid. 
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Specific Aim 2: Use the p-LAGC-EAK10 plasmid to incorporate BPTI inhibitor creating 
the lipid-anchored “inhibitor ruler”. Previous research in topography and analysis of 
serine proteases indicate that their range of attachment lies within this distance from 
the membrane surface (56, 69, 98, 99).  The engineered constructs will be sent for 
sequencing for verification. Once there is confirmation that this construct has been 
properly cloned, it will be transfected into bacterial cells for expression. Purification will 
be performed using affinity chromatography as was done in the Neuenschwander study. 
Affinity chromatography is a technique in which biochemical agents are separated based 
on specific interaction between antigen and antibody or enzyme and substrate, for 
example. Specifically, we will immobilize the enzyme trypsin to the solid support, and 
use this to separate, purify, and elute our newly generated inhibitor product from the 
remainder of the mixture.  The solution-phase inhibitory activity of each of these fXa 
inhibitors will be characterized and compared with the unmodified inhibitor. Once this is 
complete, it will be used in the next phase of the study.  
 
Materials, Methods, and Results: 
Specific Aim 1: Construction of a plasmid using a pET11d bacterial backbone containing 
the LAGC and EA3K sequences respectively (p-LAGC-EAK10). To generate a lipid-tethered 
inhibitor construct as a tool to study distances of fully pro-coagulant complex active 
sites, standard molecular cloning techniques were used (57, 78, 79, 83, 100).  Standard 
experiments in cloning usually require at least seven steps. These steps are as follows 
and include but are not limited to: 1) choosing a host organism and cloning vector, 2) 
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vector DNA purification and preparation, 3) design, preparation, and insertion of the 
desired DNA to be cloned, 4) confirmation that recombinant DNA has been created, 5) 
introduction of new DNA into host organism, 6) selection of colonies possibly containing 
new DNA, and finally, 7) screening of said clones for the appropriate biological 
properties (57, 78, 79, 83, 100).  
Choosing a Host Organism and Cloning Vector 
For this study, Escherichia coli was used as the host organism. E. coli is a bacteria 
used commonly in molecular cloning because of its versatility, availability, and ability to 
grow quickly (101) . It is these same reasons that make it a great system to use for these 
experiments.   
Upon choosing this bacterial system, the pET11d vector system was selected as 
the cloning vector (102). The pET11d system contains an ampicillin-resistance gene that 
allows selection for transformants. Other studies have used this system successfully not 
only to create recombinant DNA but for protein expression as well (101). In addition to 
antibiotic resistance, pET11d also contains unique restriction endonuclease sites, in 
particular, HindIII and NcoI sites which allows directional cloning of the LAGC and EA3K 
linkers into the vector system respectively. In Figure XIV below, a depiction of the 
pET11d vector system has been provided. Note the many cleavage sites available for 
manipulation particularly those at the HindIII, NcoI, BamHI, and XbaI sites. The design of 
each DNA insert (i.e. LAGC and EA3K) was based on these areas within pET11d (see next 
page).  
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Figure XIV. Graphic DNA map of pET11d vector.  Depicted in this map of the 5,674 
base pair plasmid are the ampicillin promoter and repressor region, lacI promoter, and 
termination sites. www.snapgene.com/pet11d 
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Preparation of Vector DNA 
Competent Cell Generation 
 Competent cells were generated using frozen glycerol stocks of DH5α cells (82). 
While still frozen, the cells are scraped onto a metal loop using sterile technique. The 
cells are then streaked onto an LB plate and incubated overnight at 37°C. The next day, 
a single well-isolated colony was selected and inoculated into 5 ml of LB in a 10-ml 
Falcon© tube. The inoculated colony was allowed to grow overnight while shaking in a 
37°C incubator at 125 rpm. Then, 1 ml of the overnight culture media was inoculated 
into 100 ml of fresh LB media. This 250-ml Erlenmeyer flask was shaken for 3 hours at 
37°C and 125 rpm to ensure the cells reached OD600nm of 0.4.  Next, the cells were 
placed on ice for 10 minutes. The cells were then transferred into pre-chilled 50 ml 
conical tubes. Cells were centrifuged at 3000 x g in a 4° C centrifuge for 10 minutes. The 
supernatant was removed and the pellet resuspended in 1.6 ml of ice cold 100 mM 
CaCl2. The cells were incubated on ice for 20 minutes. After the cells are washed twice, 
0.5 ml of cold 80% glycerol was added to the suspension. Finally, 500 µl aliquots of cells 
were prepared in 1-ml cryogenic vials and placed into a -80°C freezer for use. 
Plate Preparation 
                       To prepare LB + antibiotic plates, 800 ml of deionized water was placed in a 
large flask on a stir plate. Then, 25 g of LB mix including 10 g of tryptone, 10 g of NaCl, 
and 5 g of yeast were weighed and added to the flask (85). Next, 15 mg of agar was 
added to the flask. All components were stirred until they appeared evenly mixed. Then, 
about 200 ml of deionized water was added to the mixture and allowed to stir. Once 
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that is completed, the LB/Agar mixture was placed in an autoclave for one hour for 
sterilization. After sterilization, the mixture was allowed to cool until 60°C or less is 
reached. Then, 10 ml of ampicillin (100 mg/ml) was added to the flask. Finally, about 25 
ml of LB agar + Ampicillin was poured into each plate. The recipe makes up to 40 plates.  
  
DNA Extraction and Purification 
pET11d DNA was obtained from BL21(DE3) expression strain DNA gold stocks in 
the laboratory provided generously by Dr. Francis Jenney, Philadelphia College of 
Osteopathic Medicine—Georgia Campus. The strain was inoculated into 5 ml of Luria 
broth (LB) containing a 1:10 dilution of ampicillin (10 mg/ml) and shaken overnight at 
37°C (85). Using the Strataprep™ Plasmid Miniprep kit (Agilent Technologies, Santa 
Clara, CA), the plasmid DNA was purified using the manufacturer protocol (103).   
This purified plasmid DNA was transformed into DH5α growth strain competent 
cells. First, previously cultured DH5α competent cells were obtained from the -80° C 
freezer and thawed on ice. While the cells thawed, super optimal broth with catabolise 
repression (SOC) media was prepared using sterile super optimal broth (SOB), 1M 
MgCl2, and 40% glucose solution. Media such as this is an optimized version of LB used 
by researchers attempting to grow and express DNA plasmids in E. coli and other 
bacteria (82). SOB broth containing a mixture of bacto-tryptone, bacto-yeast extract, 
NaCl, KCl, MgCl2, MgSO4, and deionized water (85). Then, 50 µl of thawed competent 
cells were pipetted into a 1.5 ml eppendorf tube on ice. Next, 10 ng of pET11d DNA [20 
ng/µl] was pipetted into the tube and incubated on ice for 30 minutes. Once this 
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incubation was complete, the cells were heat shocked at 42°C in a water bath for 30 
seconds. Then, the cells were incubated on ice for 2 minutes. Next, 1 ml of the prepared 
SOC medium was added to the tube. The tube was then placed into a 37°C incubator for 
1 hour. After incubation, 100 µl of the cell solution was spread onto an LB + Ampicillin 
agar plate. The plate was placed into the 37°C incubator to incubate overnight.  
The pET11d DNA was extracted from these DH5α colonies in the laboratory using 
the PureYield™ Plasmid Midiprep System (103, 104). It was found that the DNA recovery 
yielded using this kit was less than ideal for this study. Thus, the Strataprep EF Plasmid 
Midiprep Kit (Cat#400721) from Stratagene was used for the remainder of the study 
(105). The protocol associated with this kit was followed using the steps described here. 
First, a single colony of DH5α cells was inoculated into 200 ml of LB culture media and 
vigorously shaking overnight at 37°C.  The next day, the bacterial culture was pelleted by 
centrifugation in 50-ml conical tubes at 4750 x g for 1 hour. The clarified supernatant 
was drained and discarded. Next, the pellets were vortexed for resuspension in the 
small amount of culture medium remaining in the tubes. After that, the resuspended 
pellets were combined into one tube. Then, 7 ml of Solution 1 was added to the tube 
and mixed vigorously with the vortex until the brown mixture turned blue in color. 
Solution 1 is a mixture of 50 mM Tris HCl, 10 mM EDTA, 50 ug/ml of RNase A, and 0.5% 
(w/v) SDS. This solution contains agents which degrade any RNA present in cells. Next, 7 
ml of Solution 2 was added to the tube. Contents were mixed by inverting the tube 
several times until the contents uniformly turned purple in color. This solution contains 
0.2 M NaOH and 1% (w/v) SDS.  Solution 2 is responsible for degrading all protein in the 
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cells. The contents in the solution have been used in other studies to degrade proteins 
(106).  After this, 2 ml of Solution 3 was added to the tube. The contents were once 
again mixed by inversion until the color changed to blue. Solution 3 is a proprietary 
reagent. Therefore, exact components are not available for public information. Once all 
3 solutions were added, the tube was centrifuged at 4750 x g for 15 minutes. This 
centrifugation resulted in a compact, light blue pellet at the bottom of the tube, a thin 
blue film on the surface of the supernatant. The supernatant was pipetted into a fresh 
50-ml conical tube taking care not to collect any of the pellet of thin film.  
Next, 10 ml of Solution 4 was added to the tubes and the contents mixed by 
inversion. Solution 4 is also proprietary, but it is a chaotropic salt which assists in 
precipitating all DNA present within the cells.  After the contents were mixed properly, 
the mixture was added to a midi-spin cup seated in a 50-ml conical tube with the cap 
tightened loosely. Sample was then centrifuged at 1500 x g for 10 minutes. The midi-
spin cup containing the plasmid DNA was removed from the 50-ml tube and liquid 
discarded. The midi-spin cup was then placed back into the 50-ml conical tube. Next, 20 
ml of wash buffer was added to the receptacle. The wash buffer contains 10 mM Tris 
HCl, 100 mM NaCl, 2.5 mM EDTA, and 10 mM Ethanol. As indicated by its name, it 
serves as a way to cleanse the DNA of any impurities that may have been caught in the 
fiber matrix of the midi-spin cup. The sample was spun at 1500 x g for 3 minutes. The 
liquid was discarded in the same manner as mentioned, and the tube was spun once 
more to ensure all wash buffer and any impurities it may contain was removed. The 
midi-spin cup was then transferred to a fresh 50-ml conical tube. Next, 500 ml of elution 
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buffer (i.e. nuclease free water) was added directly onto the fiber matrix at the bottom 
of the midi-spin cup. This was incubated at room temperature for 5 minutes. After the 
time elapsed, the tube was centrifuged at 1500 x g for 3 minutes. The purified plasmid 
DNA eluted into the receptacle was transferred to a 1.5 ml eppendorf tube.  
To determine the concentration of this DNA, gel electrophoresis was used. A 
0.8% agarose gel was used to run the negatively charged DNA toward the positive 
electrode on the electrophoresis apparatus. Agarose gels are commonly used as they 
are composed mainly of agarose, water, and 1M Tris and EDTA buffer. Agarose is a 
polysaccharide found in algae. This composition makes it easy for DNA to travel through 
the hole-filled gel. The percentage of this gel was used as it was recommended as the 
ideal percentage size of the DNA being separated (roughly 5000-6000 base pairs in size).   
About 10 µl of DNA and bromophenol blue stain (0.0025 mg/ml) were loaded onto the 
gel and run at 100V (constant voltage?) for 30 minutes. The bromophenol blue stain 
solution is composed of bromophenol sodium salt and deionized water. New England 
Biolabs Quick-load 1kb ladder used to determine the DNA size and concentration. Figure 
XV below is the DNA extracted using the aforementioned Stratagene kit.  
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Figure XV. 0.8% Agarose Gel used to determine the concentration of pET11d DNA 
extracted from Stratagene DNA Purification Kit. Lane 1 contains 10 ul of New England 
Biolabs Quick-load 1kb DNA Ladder. Lanes 2, 4, and 6 contain DNA collected from 3 
separate purification experiments. It was determined that the DNA in lanes 2 and 6 are 
pET11d. 
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Restriction Digests 
Restriction endonucleases were used to prepare the purified vector DNA for 
insertion of the custom LAGC and EA3K sequences ordered from Integrated DNA 
Technologies. These sequences were introduced at the same time and were designed to 
insert into the vector DNA in a certain order. This is known as directional cloning. 
Therefore, two sites were selected to accommodate for the sticky ends that correlate 
with these recognition sequences. For directional cloning, NcoI and HindIII sites were 
selected as the areas to be digested for insertion. Cloning in this manner has been 
completed successfully by a number of studies over the last few decades (107).  
Restriction enzymes generate sticky ends within a vector which allow for the 
insertion of foreign DNA. These sites were selected because they are unique within 
pET11d and, therefore, should cut at its only respective cleavage recognition site. The 
recognition site for NcoI from 5’ to 3’ is C/CATGG (107). For this reason, the EA3K 
sequence contains a sticky ends coding for the complementary site to NcoI. The LAGC 
sequence was designed with sticky ends that correlate with the HindIII recognition site 
A/AGCTT. To ensure that both sequences attached well with one another sticky ends for 
BamHI were included in each. The BamHI recognition site is G/GATCC (108).  This site is 
important not only to incorporate these 2 sequences, but also because this BamHI site 
was already within the pET11d vector. Cleaving the DNA with both NcoI and HindIII 
should have removed that site. Replacing this region allowed for screening of the final 
product to ensure that the foreign DNA cloned in properly. Restriction digests involve 
the following components mixed together in one tube: DNA, 10X NEB buffer, bovine 
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Table IV. Restriction Digestion with NcoI. This table represents the reaction conditions 
used to prepare pET11d for DNA insertion.  
serum albumin (BSA), ≥ 10 units of desired restriction enzyme with attention to star 
activity, and deionized water.  Bovine serum albumin is used as a reagent used to 
stabilize enzymes in restriction digests. A restriction digest using purified pET11d DNA 
was prepared using the reaction conditions listed below in Table I. These components 
were combined at the volumes listed below into a 1.5 ml eppendorf tube. The 
restriction enzyme was added last. The tube was then incubated for 1 hour at 37°C. 
After incubation, 5 µl of 1M Tris/0.1M EDTA (i.e. stop solution) was added to cease the 
reaction. 
Reaction Components Restriction Digest with NcoI (µl) Restriction Digest with NcoI  
(µl) 
Restriction Digest with NcoI (-) Control  
(µl) 
BSA 0.5 
100 µg/ml 
0.5 
100 µg/ml 
0.5 
100 µg/ml 
NEBuffer 3 
[l] = 10X  
5 
1X 
5 
1X 
5 
1X 
ddiH2O 32 32 43.5 
DNA 
[Final] = 60ng/ul 
10   
600 ng 
10 
600 ng 
1 
60 ng 
Restriction Enzyme 
10 units/µl 
2.5 
25 u 
2.5 
25 u 
2.5 
25 u 
Total 50 50 50 
  
 
After the digestion was complete, the digested DNA was loaded onto a 0.8% 
agarose gel and run on a gel electrophoresis apparatus at 100V for 45 minutes. Upon 
viewing the gel using the [Alpha Imager], the desired band was excised from the gel 
using a razor and placed into a 15 ml conical tube. After excision, the Strataprep DNA 
Gel Extraction Kit (Cat #400766) was used to extract the DNA from the agarose gel. 
Specifically, 6.36 ml of extraction buffer was added to the 15-ml conical tube. Then, the 
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tube was incubated in a 50°C water bath for 10 minutes (mixing occasionally). After the 
gel was completely dissolved, the mixture was transferred to a 2-ml receptacle with a 
microspin cup seated in it. Due to volume, 825 µl of the mixture was transferred at a 
time. After the mixture was transferred, the tube is centrifuged in a microcentrifuge at 
14,000 x g for 30 seconds. The DNA is retained in the fiber matrix of the microspin cup. 
Thus, after centrifugation, the liquid was decanted. This process was repeated until all 
the liquid had been centrifuged and decanted. Then, 750 µl of wash buffer (with 100% 
ethanol added) was pipetted into the microspin cup. The tube was centrifuged at 14,000 
x g for 30 seconds. The wash buffer was decanted, and the tube was centrifuged at 
14,000 x g for 30 seconds ensure that all wash buffer was removed. The micro-spin cup 
was then transferred to a fresh 2-ml receptacle tube. Then, 50 µl of elution buffer was 
added directly on top of the fiber matrix of the micro-spin cup and incubated for 5 
minutes. Lastly, the tube is centrifuged at 14,000 x g for 30 seconds. The extracted 
pET11d + NcoI DNA was seated in the 2-ml receptacle tube. Figure XVI below is a 
depiction of the NcoI digest that was gel extracted.  
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Figure XVI. Restriction Digest with NcoI. 0.8% agarose gel of 
pET11d digested with NcoI and gel extracted using Strataprep 
DNA Gel Extraction kit. 
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Next, the gel extracted DNA was digested with HindIII. This experiment was 
conducted in the exact manner as the NcoI digest. However, a gel electrophoresis 
experiment and extraction were not necessary as this second digestion would be 
indistinguishable from the first digestion.   
Dephosphorylation 
Next, the pET11d + NcoI + HindIII was treated using New England Biolabs Calf 
Intestinal Alkaline Phosphatase (AP-CIP). This was done as a precautionary measure to 
ensure that the sticky ends generated by the restriction enzyme digests could not close 
before any foreign sequences could be introduced.   Alkaline phosphatase works by 
removing the phosphate group (PO4-3) from the 5’ end of DNA strands (109). DNA 
treatment with AP-CIP is carried out in a similar manner to a restriction enzyme 
digestion. Therefore, Table V below is a representation of the reaction conditions the 
DNA was exposed to for dephosphorylation.  
 
 
 
 
 
 
 
 
Reaction Components Amount used (ul) 
 10X NEB Buffer 3 11 
1X 
Calf Intestinal Alkaline Phosphatase  
(10 units/µl) 
1 
10 u 
DNA 
5.5 ng/µl 
96 
528 ng 
ddiH2O 2 
Total 110 
Table V. Dephosphorylation of pET11d + NcoI + HindIII 
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Water, NEB buffer 3, AP-CIP, and DNA were combined in 1.5 ml eppendorf tube and 
incubated for 1 hour in a 37°C incubator. Figure XVII A/B is an agarose gel depicting 
double digested pET11d after treatment with AP-CIP and gel extracted for use.     
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Figure XVII A and B. 0.8% agarose gel with alkaline phosphatase treated DNA. Lane 1 
is QL 1kb ladder and Lane 3 is dephosphorylated pET11d backbone DNA.  
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Preparation of Insert DNA 
As mentioned previously, the LAGC and EA3K linker oligonucleotide sequences 
were designed and purchased through Integrated DNA Technologies. Among its 
services, this company provides custom oligonucleotide synthesis using artificial gene 
synthesis.  Gene synthesis techniques have been used since the 1970s to generate 
usable, customizable DNA constructs.  Nucleoside phosphoramidites are synthetic 
building blocks used to construct oligonucleotides added one at a time to create a chain. 
Currently, oligonucleotide sequences can be ordered at a length of up to 200 base pairs 
each. Goeddel et al generated synthetic insulin using synthetic techniques including PCR 
and radioimmunoassay (110).  These synthetic DNA sequences are generated in forward 
and reverse sequences which are shipped in lyophilized conditions at a 20 nmole 
concentration. Thus, it was necessary to re-suspend each one in the appropriate buffer.  
Figure XVIII is a depiction of oligonucleotide synthesis and how oligonucleotides with 
sticky ends anneal to each other.  
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Figure XVIII A and B. A—Oligonucleotide Synthesis. B--General Annealing of 
Oligonucleotides with Sticky Ends. 
80 
 
Fresh, sterilized 10 mM Tris/ 1mM EDTA buffer was selected as the re-
suspension buffer. This media was recommended by the manufacturers because its 
composition provides a constant pH environment for the synthetic DNA. First, each oligo 
tube was centrifuged at 14,000 x g for 30 seconds to ensure none of the lyophilized 
product is lost when the tube is opened. Then, approximately 200 µl of this buffer was 
added to each lyophilized oligo pellet for a final concentration of 100 uM respectively. 
This amount was added based on IDT recommendations to suspend as follows: 
# nmole x 10 µl/nmole = x µl TE buffer to be added for [100 uM] 
After re-suspension, the oligonucleotides were placed in the -20°C freezer. For 
use, each oligo forward and reverse sequence was annealed at a 1:1 molar ratio. This is 
completed as indicated by Table III below. First, 500 ml of water was heated in a beaker 
until it reached 95°C. Then, 10 µl of nuclease free water was added to an eppendorf 
tube. Next, 5 µl of DNA per oligo in µl was placed into the tube. Once these components 
are combined, the tube containing the combined oligonucleotide sequences was placed 
into the water beaker which was heated until the temperature of the water was 95°C.  
Annealing began once that tube was placed into the beaker and the water temperature 
was allowed to decline until a temperature of 30°C was reached. Confirmation that 
annealing occurred was verified using gel electrophoresis as depicted below in Figure 
XIX. A successfully annealed oligonucleotide will display a band at the expected size on 
the agarose gel. In this case, a band would be visible near the 100 bp rung for the LAGC 
oligonucleotide and near the 200 bp rung for the EA3K linker. If annealing did not take 
81 
 
Table VI. This table contains the components used 
to anneal the oligonucleotides. Components were 
combined and heated in a 95°C water beaker until 
the water reached 30°C. 
place, it is possible that a band may not be visible on the gel at all. Furthermore, an 
incomplete or incorrect annealing may be denoted by a smear on the gel.  
 
 
  
 
 
 
 
 
 
 
 
LAGC EA3K Linker 
100 µM LAGC-Fwd 
5 μl 
100 µM Linker-Fwd 
5 μl 
100 µM LAGC-Rev 
5 μl 
100 µM Linker-Rev 
5 μl 
10 uL ddiH2O 10 ul ddiH2O 
 [Final] = 50 µM 
20 μl 
 
 [Final] = 50 µM 
20 μl  
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Figure XIX. 0.8% Agarose Gel with Annealed LAGC and EA3K 
Linker Oligonucleotides. 
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Insertion of LAGC and EA3K Linker DNA into pET11d 
     Ligation 
                  The dephosphorylated pET11d + NcoI + HindIII, LAGC, and EA3K Linker DNA 
were combined in the attempt to create recombinant DNA using T4DNA ligase (New 
England Biolabs, Ipswich, MA). This reaction was set up such that a 3:1 insert-vector 
ratio was used. The exact reaction components and volumes are listed below in Table 
IV. Once all calculations were complete to ensure the insert-vector ratio was as 
expected, the components were mixed together making sure to pipet each gently into a 
0.5 ml strip eppendorf tube. The tubes were then placed into the Thermocycler© PCR 
machine to be incubated overnight at 16°C. 
 
REACTION COMPONENTS LIGATION #1  LIGATION #2 (CONTROL)  
10X T4 DNA LIGASE BUFFER* 
~NEB#3 
3 μl 
[Final] = 1X 
3µl 
[Final] = 1X 
VECTOR DNA (5.674 KB) 20 μl 
100 ng 
 20μl 
100 ng 
LAGC INSERT DNA (75 BP) 0.34 μl 
300 ng 
0.34 μl 
300 ng 
EA3K LINKER INSERT DNA (171 BP) 0.8 μl 
300 ng 
0.8 μl 
300 ng 
DDIH2O 4.86 μl 5.86 μl 
T4 DNA LIGASE 
10 UNITS/µL 
1 μl 
10 u/ µl 
0 μl 
0 u/ µl 
TOTAL 30 μl  30 μl  
Table VII. Ligation of pET11d backbone DNA with LAGC and EA3K Linker 
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Introduction of Recombinant DNA into Host Organism 
                     The tubes were retrieved from the thermocycler and chilled on ice. DH5α 
competent cells retrieved from the -80°C freezer were thawed on ice for 10 minutes. An 
aliquot of 50 µl of these thawed cells were placed into 14 ml tubes for ligation 1, ligation 
2 (- control), and pUC18 DNA (+ control/transformation efficiency). This is 
transformation process is very closely related to the one done for obtaining pET11d DNA 
as mentioned previously. About 3 µl of DNA (or 10 ng) from ligation 1, ligation 2, and 
pUC18 were added to its respective tube carefully. The tubes were then incubated on 
ice for 30 minutes. Then, the cells were heat shocked at 42°C for exactly 30 seconds. 
Next, tubes were placed on ice for an additional 2 minutes. Then, 250 µl of pre-warmed, 
pre-prepared SOC without antibiotics was added to each tube. Next, the tubes were 
placed in a 37°C incubator to be shaken for 1 hour at 225 rotations per minute (RPM). 
While this shaking was taking place, six LB + Ampicillin plates were labeled and prepared 
for plating of the cells. When the one hour incubation was complete, a volume of cells 
were spread on each plate in the as described in Table III below. Once cells were spread 
on each plate, they were allowed to dry and placed into the 37°C incubator overnight.  
LB + Ampicillin 
Plate 
Ligation #1 Ligation #2 (- 
control) 
pUC18 (+ control) 
1 100 µl cells only 100 µl cells only 100 µl cells only 
2 100 µl LB + 10 µl 
cells 
100 µl LB + 10 µl 
cells 
100 µl LB + 10 µl 
cells 
 Table VIII. This table correlates to the six plates total from this transformation experiment. 
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Selection of Colonies Possibly Containing Recombinant DNA 
      The next day, the six plates were collected and observed for growth of colonies. A 
number of colonies was observed on four of the six plates total. These four plates 
included the set from ligation 1 as well as the pUC18 plate. Figure XX below is one 
representative plate from each set of plates.  
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Figure XX. Observation of LB/AMP plates containing colonies with possible recombinant 
pET11d DNA. 
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For organizational purposes, ligation plate 1 containing possible recombinant pET11d 
DNA was divided into quadrants A, B, C, and D. After selecting quadrants, each well-
isolated colony (WICs) in each quadrant was counted and given a number. The number 
of WICs per quadrant is listed as follows: A-6, B-5, C-6, and D-4.  Table VI below indicates 
the total number of colonies counted on each plate regardless of whether or not they 
were well-isolated or not. 
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Ligation Plates Plate #1 Plate #2 
pET11d + LAGC + Linker 31 0 
control 0 0 
pUC18 TMC TMC 
 
Each of these WICs was streaked on LB + Ampicillin agar plate and grown overnight at 
37C. Then, the cells were collected by sterile technique and inoculated into 5 ml of 
sterilized LB broth with ampicillin (50 ug/ml). These inoculated colonies were allowed to 
grow overnight in a 37°C shaking incubator. The next day, DNA purification using the 
Strataprep© EF Plasmid Miniprep kit was performed on each colony. The protocol for 
this kit was followed as listed in a previous section. Figure XXI has been provided to 
accurately depict each quadrant on the LB + Ampicillin plate in this experiment.  
Table IX. Ligation Colony Count. Plates with colonies too numerous to count are listed 
as TMC. 
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Figure XXI. Ligation 1 plate 1 quadrants A-D and their associated colony growth. 
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Screening for Clones with Appropriate Biological Properties 
     As mentioned previously, the design of this recombinant DNA included a number of 
unique restriction sites within the plasmid that would allow the identification of 
plasmids containing the correct sequence. The BamHI site within recombinant pET11d 
indicates that ligation and transformation efforts were successful.  
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Figure XXII. Vector Map of Predicted Recombinant DNA including BamHI site.  
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Thus, upon DNA purification, each colony was digested with BamHI. The protocol for 
this restriction digest is nearly exact to that mentioned in the restriction digest section 
above. Table V below is a depiction of the conditions of which the purified recombinant 
DNA was treated. 
Components A-D purified colonies (ul) 
BSA 0.5 
NEB Buffer 3 5 
DNA 
[ ] = 40 ng/ul 
10 
BamHI 2 
ddiH2O 25 
Total 30 
 
 
Pre-Screening of Recombinant Colonies 
     Each colony was successfully digested with BamHI. Of the 21 colonies collected and 
purified, a total of 4 appeared to linearize the DNA at the expected size for the 
recombinant pET11d DNA. These colonies containing possible recombinant DNA will be 
referred to as p-LAGC-LINKER for the remainder of the publication. Figure XV A-D 
represents the restriction digests correlating to quadrants A, B, C, and D (see Figure XIII).                 
  
Table X. Restriction Digest with BamHI 
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Figure XV A, B, C, and D. Each of these 0.8% agarose gels correlate with their 
corresponding letters. A restriction digest with BamHI was performed on each colony. 
Undigested colonies are listed as uncut. The lanes of each gel are denoted in blue below. 
The colonies expected to contain the appropriate sequence are circled. 
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               Table XI depicts which colonies were expected to contain p-LAGC-LINKER DNA. 
They are circled and indicated in the table below. It appeared that quadrant A contained 
at least two colonies that could possibly be the correct sequence. Quadrant B did not 
appear to have a single colony digest the DNA at the appropriate size. Both quadrants C 
and D contained one colony that demonstrated a linearized band at the correct size. 
 
 
 
 
 
 
          
 
After the pre-screening tests were completed, the purified DNA from all of these 
colonies was sent for DNA sequencing at Retrogen Technologies. Because the pET11d 
vector contains a T7 promoter primer (5' TAA TAC GAC TCA CTA TAG GG 3')  as well as a 
T7 terminator sequence primer (5' GCT AGT TAT TGC TCA GCG G 3') on either side of the 
targeted insert site, The data from Retrogen can be found in the Appendix: Sequencing 
Data section of this publication. The data indicate that colony A1 contained the 
sequence correlating with what was expected should the LAGC and EA3K Linker 
sequences have incorporated properly. Figure XXIV below is a depiction of this data.  
 
Restriction Digest with BamHI 
Quadrant Colony 1 Colony 2 Colony 3 Colony 4 Colony 5 Colony 6 
A +  -  +  - -  -  
B -  -  - - - None 
C  - -  -  - - + 
D  - +  - - None  None  
Table XI. Pre-Screening Colonies with BamHI. + indicates linearized DNA band at 
expected size. – denotes that DNA did not linearize at the expected size. 
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Figure XXIV. Data Analysis of recombinant DNA received from 
Retrogen Technologies. A color coded sequence map is included.  
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Upon confirmation that the colony A1 contained p-LAGC-LINKER DNA, the plasmid was 
given the name p-LAGC-EAK10.  
Specific Aim 2: Use the p-LAGC-EAK10 plasmid to incorporate BPTI inhibitor creating the 
lipid-anchored “inhibitor ruler”.   Once it was confirmed that the LAGC and EA3K 
sequences were properly introduced into pET11d generating a new plasmid named p-
LAGC-EAK10, an attempt to introduce the BPTI sequence into the recombinant DNA 
downstream from the EA3K linker region was done. This process is identical to that of 
techniques performed in Specific Aim #1. A graphic map of the current plasmid can be 
found in Figure XXV below depicting the unique restriction sites within the vector.  
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p-LAGC-EAK10 
Figure XXV. Graphic map of p-LAGC-EAK10 
Serial Cloner 2.6 
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p-LAGC-EAK10 DNA Purification  
         Using techniques as outlined in Specific Aim #1 in the DNA purification section, 
DH5α cells containing p-LAGC-EAK10 DNA was grown in 500 ml of LB broth with 
ampicillin, and DNA harvested as described in Materials and Methods section. To 
confirm this DNA had been properly purified, it was separated on an agarose gel at 100V 
for 45 minutes. The plasmid DNA was observed on the gel exhibiting two crisp bands 
below the 8,000 bp rung, which indicated that the DNA was successfully purified. 
Multiple bands are common with circularized DNA as it is often supercoiled. One band 
ran very high, while the other was observed much lower on the gel suggesting nicked 
DNA.  
Sequential Restriction Digests using NcoI and XbaI 
          BPTI inhibitor DNA insert oligonucleotides were designed to contain sticky ends 
correlating to unique cutting sites of NcoI and XbaI within recombinant p-LAGC-EAK10 
DNA. Therefore, recombinant p-LAGC-EAK10 was cleaved open beginning with the 
restriction endonuclease XbaI.  
Reaction Components Restriction Digest with XbaI (µl) Restriction Digest with XbaI (-) Control  
(µl) 
BSA 0.5 
100 µg/ml 
0.5 
100 µg/ml 
NEBuffer 3 
[l] = 10X  
5 
1X 
5 
1X 
ddiH2O 22 43.5 
DNA 
[Final] = 50ng/ul 
20   
1000 ng 
1 
50 ng 
Restriction Enzyme 
10 units/µl 
2.5 
25 u 
0 
0 u 
Total 50 50 
 Table XII. p-LAGC-EAK10 Restriction Digest with XbaI 
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           The DNA and all necessary components as listed above were combined in a 1.5 ml 
eppendorf tube and incubated at 37°C for 1 hour. Upon digestion, stop solution 
(containing EDTA) was added to cease enzymatic activity. Then, DNA was loaded onto a 
0.8% agarose gel and run at 100V for 45 minutes. After gel separation, the band 
corresponding to the size of linearized DNA (≈ 5700 bp) was excised and gel extraction 
was performed.  
Reaction Components Restriction Digest with NcoI (µl) Restriction Digest with NcoI (-) Control  
(µl) 
BSA 0.5 
100 µg/ml 
0.5 
100 µg/ml 
NEBuffer 3 
[l] = 10X  
5 
1X 
5 
1X 
ddiH2O 18 43.5 
DNA 
[Final] = 21ng/ul 
24   
500 ng 
1 
21 ng 
Restriction Enzyme 
10 units/µl 
2.5 
25 u 
0 
0 u 
Total 50 50 
 
Once extracted, the DNA was combined with all necessary components as listed above 
and digested with NcoI. Once this process was completed, the p-LAGC-EAK10 DNA was 
dephosphorylated in a 37°C incubator using AP-CIP as described below.  
 
 
 
 
 
 
Reaction Components Amount used (ul) 
 10X NEB Buffer 3 11 
1X 
Calf Intestinal Alkaline Phosphatase  
(10 units/µl) 
1 
10 u 
DNA 
5 ng/µl 
96 
480 ng 
ddiH2O 2 
Total 110 
Table XIII. p-LAGC-EAK10/XbaI Restriction Digest with NcoI 
Table XIV. p-LAGC-EAK10/XbaI/NcoI Restriction Digest with AP-CIP 
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BPTI insertion into p-LAGC-EAK10 recombinant DNA 
            As mentioned, the BPTI forward and reverse oligonucleotides were designed to 
contain sticky ends correlating to the recognition sites for NcoI and XbaI. The 
recognition site for XbaI is T/CTAGA. Because this sequence was purchased as forward 
and reverse sequences as the other oligonucleotides were, it was necessary to anneal it 
using the same technique as listed in Specific Aim #1. The size of the annealed product 
should be 189 base pairs.  Figure XXVI is a 0.8% gel depicting the annealed DNA that 
correlates to the size of the designed BPTI insert. Smearing around the predominant 
band can be explained by the overloading of the DNA, misalignment of the annealed 
product, or potentially degraded DNA.  
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Figure XXVI.  Annealed BPTI product on a 0.8% agarose gel. Lane 1 is QL 
1kb ladder. Lane 2 is 100 bp ladder. Lane 3 is annealed BPTI product 
about 189 bp in size. 
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The reaction components of this ligation are listed below. This ligation was conducted 
using the protocol as outlined in the previous sections.  
 
 
 
 
 
 
 
 
 
 
 
Introduction of recombinant p-LAGC-EAK10 DNA into Host Organism 
         After the ligation was complete, a transformation was performed using the 
techniques outlined in a previous section. DH5α competent cells were used in this 
experiment as in the transformation prior to this. Once the transformation was finished, 
five LB + Ampicillin plates were used to spread the ligation and control cells for 
overnight incubation in a 37°C incubator.  
Selection and Screening of recombinant p-LAGC-EAK10 Colonies 
         The next day, the LB + Ampicillin plates were collected and observed for growth of 
any colonies. Of all the plates, none of them contained colonies for screening. Ligation 
REACTION COMPONENTS 3:1 LIGATION  P-LAGC-EAK10/XBAI/NCOI   
10X T4 DNA LIGASE BUFFER*  3 μl 
[Final] = 1X 
3µl 
[Final] = 1X 
VECTOR DNA (5.674 KB) (5 ng/µl) 20 μl 
100 ng 
 20μl 
100 ng 
BPTI INSERT DNA (189 BP) (177 ng/ 
µl) 
1.7 μl 
300 ng 
1.7 
300 ng 
DDIH2O 4.3 μl 4.3 μl 
T4 DNA LIGASE 
10 UNITS/µL 
1 μl 
10 u/ µl 
0 μl 
0 u/ µl 
TOTAL 30 μl  30 μl  
Table XV. Ligation of p-LAGC-EAK10 and BPTI  
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experiments were repeated as described as well as with the addition of troubleshooting 
steps. Multiple troubleshooting attempts were made to remedy any possible reasons for 
unsuccessful colony growth.  
Troubleshooting 
          Because the plates from the initial ligation of p-LAGC-EAK10 and BPTI were void of 
colony growth, it was necessary to evaluate for possible issues that would lead the 
experiment to be unsuccessful. 
 Attempt 1 
In an effort to increase the chances of insertion, a second ligation experiment 
using insert-vector ratios of 3:1. 6:1, and 9:1 were completed. All other conditions and 
components remained the same. The experiment was carried out as described in the 
Materials and Methods section. To ensure that the issue was not the DH5α competent 
cells pUC18 DNA was transformed into the cells. In addition to the pUC18 DNA, a 
ligation using no insert was used as a control. No colonies were observed on those 
plates. While no colonies were observed on any of the ligation plates including the 
ligation without insert, no growth was observed on the pUC18 plate either. Photos of 
this attempt were not recorded.  
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Attempt 2 
Because no growth was observed on any of the plates, the viability of the 
competent cells was in question. A set of competent cells were prepared using the 
techniques described in the Materials and Methods section. After the cells were 
prepared, the viability of the competent cells was confirmed by transformation of 
pUC18 DNA as described previously. Another ligation attempt was made by protocol 
using the conditions in Attempt 1 previously. Though the pUC18 positive control plate 
set contained colony growth, ligation colonies were not observed.  
 
REACTION 
COMPONENTS 
3:1 LIGATION  6:1 LIGATION  9:1 LIGATION  P-LAGC-EAK10/XBAI/NCOI   
10X T4 DNA LIGASE 
BUFFER*  
3 μl 
[Final] = 1X 
3 μl 
[Final] = 1X 
3 μl 
[Final] = 1X 
3µl 
[Final] = 1X 
VECTOR DNA (5.674 
KB) (5 ng/µl) 
20 μl 
100 ng 
20 μl 
100 ng 
20 μl 
100 ng 
 20μl 
100 ng 
BPTI INSERT DNA 
(189 BP) (177 ng/ 
µl) 
1.7 μl 
300 ng 
3.4 μl 
600 ng 
5.1 μl 
900 ng 
1.7 
300 ng 
DDIH2O 4.3 μl 2.6 μl 0.9 μl 4.3 μl 
T4 DNA LIGASE 
10 UNITS/µL 
1 μl 
10 u/ µl 
1 μl 
10 u/ µl 
1 μl 
10 u/ µl 
0 μl 
0 u/ µl 
TOTAL 30 μl 30 μl 30 μl  30 μl  
Table XVI. Ligation Attempt 1 
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Attempt 3 
Once the viability of the competent cells was re-established but not colonies 
growing on the ligation plates, it was suspected that there may be an issue with the p-
LAGC-EAK10 plasmid DNA itself. So, an experiment was performed using the same 
components as above with pUC18 DNA as a positive control along with uncut p-LAGC-
EAK10 plasmid DNA and p-LAGC-EAK10/XbaI/NcoI with all other components except 
oligonucleotide inserts.  
REACTION 
COMPONENTS 
3:1 LIGATION  6:1 LIGATION  9:1 LIGATION  P-LAGC-EAK10/XBAI/NCOI 
10X T4 DNA LIGASE 
BUFFER*  
3 μl 
[Final] = 1X 
3 μl 
[Final] = 1X 
3 μl 
[Final] = 1X 
3µl 
[Final] = 1X 
VECTOR DNA (5.674 
KB) (5 ng/µl) 
20 μl 
100 ng 
20 μl 
100 ng 
20 μl 
100 ng 
 20μl 
100 ng 
BPTI INSERT DNA 
(189 BP) (177 
ng/µl) 
1.7 μl 
300 ng 
3.4 μl 
600 ng 
5.1 μl 
900 ng 
0 
0 ng 
DDIH2O 4.3 μl 2.6 μl 0.9 μl 5.0 μl 
T4 DNA LIGASE 
10 UNITS/µL 
1 μl 
10 u/ µl 
1 μl 
10 u/ µl 
1 μl 
10 u/ µl 
1 μl 
0 u/ µl 
TOTAL 30 μl 30 μl 30 μl  30 μl  
REACTION 
COMPONENTS 
3:1 LIGATION  6:1 LIGATION  9:1 LIGATION  P-LAGC-
EAK10/XBAI/NCOI  
PUC18 P-LAGC-
EAK10 
10X T4 DNA 
LIGASE 
BUFFER*  
3 μl 
[Final] = 1X 
3 μl 
[Final] = 1X 
3 μl 
[Final] = 1X 
3µl 
[Final] = 1X 
N/A N/A 
Table XVII. Ligation Attempt 2 
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This ligation attempt was made by protocol using the conditions (1 hour, 37°C) 
previously. Though the pUC18 and uncut p-LAGC-EAK10 positive control plate sets 
contained colony growth, ligation colonies were not observed on any other plate. 
 
Attempt 4 
No colonies were observed on the ligation plates including the control plate 
without insert. This plasmid demonstrated viability in past experiment, but it was 
possible that there was an issue with any one of the ligation components. The protocol 
associated with the T4 DNA ligase enzyme states that it contains ATP (adenosine 
triphosphate) which catalyzes the ligation of the DNA strands. It also states that multiple 
freezing and thawing of this enzyme is not recommended as ATP becomes deactivated 
after multiple thaws. For this reason, a set of ligations at 3:1, 6:1, 9:1, and 12:1 insert-
VECTOR DNA 
(5.674 KB) (5 
ng/ µl) 
20 μl 
100 ng 
20 μl 
100 ng 
20 μl 
100 ng 
 20μl 
100 ng 
N/A N/A 
BPTI INSERT 
DNA (189 BP) 
(177 ng/µl)  
1.7 μl 
300 ng 
3.4 μl 
600 ng 
5.1 μl 
900 ng 
0 
0 ng 
N/A N/A 
DDIH2O 4.3 μl 2.6 μl 0.9 μl 5.0 μl N/A N/A 
T4 DNA 
LIGASE 
10 UNITS/µL 
1 μl 
10 u/ µl 
1 μl 
10 u/ µl 
1 μl 
10 u/ µl 
1 μl 
0 u/ µl 
N/A N/A 
TOTAL 30 μl 30 μl 30 μl  30 μl  N/A N/A 
Table XVIII. Ligation Attempt 3 
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vector ratios was set up using a fresh vial of T4 DNA Ligase and using LB broth alongside 
a set cultured in SOC. All other components remained the same.  
 
 
After the overnight incubation at 37°C, colonies cultured in SOC were observed 
on the 9:1 plates. A lawn of colonies was recorded on these plates. Figure XXVII below is 
the image of this plate.  
  
REACTION 
COMPONENTS 
3:1 LIGATION  6:1 LIGATION  9:1 LIGATION  12:1 
LIGATION 
P-LAGC-
EAK10/XBAI/NCOI 
PUC18 
NEW 10X T4 
DNA LIGASE 
BUFFER*  
3 μl 
[Final] = 1X 
3 μl 
[Final] = 1X 
3 μl 
[Final] = 1X 
3 μl 
[Final] = 1X 
3µl 
[Final] = 1X 
N/A 
VECTOR DNA 
(5.674 KB) (5 
ng/µl) 
20 μl 
100 ng 
20 μl 
100 ng 
20 μl 
100 ng 
20 μl 
100 ng 
 20μl 
100 ng 
N/A 
BPTI INSERT 
DNA (189 BP) 
(177 ng/ul) 
1.7 μl 
300 ng 
3.4 μl 
600 ng 
5.1 μl 
900 ng 
6.8 μl 
900 ng 
0 
0 ng 
N/A 
DDIH2O 4.3 μl 2.6 μl 0.9 μl 0 μl 5.0 μl N/A 
T4 DNA 
LIGASE 
10 UNITS/µL 
1 μl 
10 u/ µl 
1 μl 
10 u/ µl 
1 μl 
10 u/ µl 
1 μl 
10 u/ µl 
1 μl 
0 u/ µl 
N/A 
TOTAL 30 μl 30 μl 30 μl 30.8 μl  30 μl  N/A 
Table XIX. Ligation Attempt 4 
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Figure XXVII. 9:1 Insert-Vector Ratio Ligation Plate 
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It was necessary to re-plate these cells at a 1:100 dilution for more well-isolated 
colonies. The next day, the plate was obtained and observed for colonies. No colonies 
were present. It can be surmised that the transformed DNA was plated at a 
concentration that was too high which allowed for a lawn to grow successfully on the 
plate. It is possible antibiotic concentration played a role as well. Therefore, when 
plated at a lower concentration no cell growth occurred. Another possibility there may 
have been confusion between the positive control and ligation sample by technician 
error. Finally, there is a possibility that a lawn grew because the ampicillin concentration 
was too high or too low to allow colony growth at the appropriate rate.  
 Attempt 5 
Although all these adjustments to the ligation experiment had not induced much 
successful colony growth, it was determined over the last few experiments that 6:1 and 
9:1 ratios were the most effective in colony growth. Also, the fresh T4 DNA ligase 
appeared to have a small role in the growth of colonies seen in Attempt 4. So, a set of 
ligations using 6:1 and 9:1 insert-vector ratios was set up using T4 DNA ligase and 
additional ATP from a stock solution concentrated at 10 mg/ml. All other components 
and conditions remained the same.  
REACTION 
COMPONENTS 
6:1 LIGATION  9:1 LIGATION  P-LAGC-EAK10/XBAI/NCOI PUC18 
10X T4 DNA LIGASE 
BUFFER*  
3 μl 
[Final] = 1X 
3 μl 
[Final] = 1X 
3µl 
[Final] = 1X 
N/A 
ATP  
10 MG/ML 
1 µl 
0.1 mg/ml 
1 µl 
0.1 mg/ml 
1 µl 
0.1 mg/ml 
N/A 
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The following day colonies were observed on both 6:1 and 9:1 plates. There was 
a total of 4 colonies are organized in plates E and F. Plate E contained 3 well-isolated 
colonies while plate 4 contained a single well-isolated colony.  
 
Pre-screening and Data Analysis for Possible Recombinant DNA 
All well-isolated colonies were cultured and collected for DNA purification using 
the Strataprep™ kit (see protocol in DNA Purification section). Once the DNA from these 
colonies was properly extracted, pre-screening the DNA with XhoI was necessary. As 
indicated in Figure XXVIII, BPTI contains a unique XhoI site within the sequence of the 
expected vector. The recognition site for XhoI is C/TCGAG. Any colony DNA exhibiting a 
linearized band between 5 and 6kb could potentially contain the desired recombinant 
DNA. The results from these experiments are listed below.  
 
VECTOR DNA (5.674 
KB) (5 ng/µl) 
20 μl 
100 ng 
20 μl 
100 ng 
 20μl 
100 ng 
N/A 
BPTI INSERT DNA 
(189 BP) (177 
ng/µl) 
3.4 μl 
600 ng 
5.1 μl 
900 ng 
0 
0 ng 
N/A 
DDIH2O 1.6 μl 0.9 μl 4.0 μl N/A 
T4 DNA LIGASE 
10 UNITS/µL 
1 μl 
10 u/ µl 
1 μl 
10 u/ µl 
1 μl 
0 u/ µl 
N/A 
TOTAL 30 μl 31 μl  30 μl  N/A 
Table XX. Ligation Attempt 5 
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Figure XXVIII. Ligation colonies digested with XhoI.  
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Screening results suggested that though DNA was successfully ligated, none of the 
colonies incorporated the BPTI DNA into the vector. Though the results suggested the 
ligation was unsuccessful, the purified DNA colonies were sent to Retrogen for 
sequencing. The data collected at Retrogen yielded the same conclusion.  
 Attempt 6 
The addition of ATP to this ligation appears to have assisted the reaction 
successfully. Thus, a final ligation attempt was made using the exact conditions as 
Attempt 5 in anticipation that the results would be more successful.  
 
 
REACTION 
COMPONENTS 
6:1 LIGATION  9:1 LIGATION  P-LAGC-EAK10/XBAI/NCOI PUC18 
10X T4 DNA LIGASE 
BUFFER*  
3 μl 
[Final] = 1X 
3 μl 
[Final] = 1X 
3µl 
[Final] = 1X 
N/A 
ATP  
10 MG/ML 
1 µl 
0.1 mg/ml 
1 µl 
0.1 mg/ml 
1 µl 
0.1 mg/ml 
N/A 
VECTOR DNA (5.674 
KB) (5 ng/µl) 
20 μl 
100 ng 
20 μl 
100 ng 
 20μl 
100 ng 
N/A 
BPTI INSERT DNA 
(189 BP) (177 
ng/µl) 
3.4 μl 
600 ng 
5.1 μl 
900 ng 
0 
0 ng 
N/A 
DDIH2O 1.6 μl 0.9 μl 4.0 μl N/A 
T4 DNA LIGASE 
10 UNITS/µL 
1 μl 
10 u/ µl 
1 μl 
10 u/ µl 
1 μl 
0 u/ µl 
N/A 
TOTAL 30 μl 31 μl  30 μl  N/A 
Table XXI. Ligation Attempt 6 
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After transformation and overnight growth, the six plates were retrieved and 
observed for colony growth. Of the six plates, four plates including one of the 6:1 and 
one of the 9:1 contained colonies. The other two plates were the controls pUC18 and p-
LAGC-EAK10/XbaI/NcoI without insert.  The plates were divided into plates G and H. 
Plate G represented the 6:1 ratio colonies. Plate H was the 9:1 ratio plates. Figure XXIX is 
a depiction of these plates. 
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Figure XXIX. Ligation Plates G, H, and p-LAGC-EAK10 without insert. 
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These colonies were cultured and DNA purified as described previously. Screening of 
these colonies by restriction digest with XhoI was performed. Figure XXX A and B is a 
depiction of the results of this digest.  
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Figure XXX. Restriction Digest with XhoI. Lanes are denoted in blue.  
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According to the screening results, H6 appeared to be the only colony that could 
possibly contain the recombinant DNA as the plasmid compared to the undigested 
plasmid generated a crisp band at the expected digestion site. All the colonies were sent 
for sequencing at Retrogen. The data analysis indicates that no recombinant DNA was 
obtained. One possible reason for this is that the annealed BPTI product contained 
smears when observed on a 0.8% agarose gel. This suggests that the DNA misaligned 
and therefore would not allow the sticky ends to associate properly with the linearized 
p-LAGC-EAK10 vector.  
 
Discussion: 
Molecular cloning is a multi-step process involving several that are time 
consuming and unpredictable. As mentioned previously, generating recombinant DNA 
involves choosing a host organism and orchestrating conditions in which to linearize the 
vector, insert a foreign insert, and circularize the DNA. Upon circularization of 
recombinant DNA, sequencing is necessary to confirm the incorporation of foreign DNA 
insertions. This project was limited in the time frame allowed to complete experiments. 
While p-LAGC-EAK10 was generated successfully during the course of this project, 
several unsuccessful attempts to incorporate BPTI into the p-LAGC-EAK10 vector were 
made.  
Possible issues for this have been listed previously including non-viable 
competent cells, deactivated ligation enzyme, and a low concentration of ATP necessary 
for ligation. Other possible issues to address could be the potentially misaligned 
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oligonucleotide annealed product. Perhaps, adjusting the annealing protocol by 
temperature or time frame would allow for a more successful annealing of the forward 
and reverse sequences.  
 
Future Aims:  
BPTI Incorporation into p-LAGC-EAK10 
 As this study ended with unsuccessful attempts to incorporate BPTI into the p-
LAGC-EAK10 plasmid, the following are suggestions regarding the continuation of this 
research. First, increasing the insert to vector ratio would allow the annealed 
oligonucleotide more opportunities to incorporate properly into the plasmid.  
Expression & Purification of Inhibitor Ruler  
Next, expression of the BPTI-lipid anchored “inhibitor ruler” in the BL21(DE3) 
expression strain followed by detection of the protein using Western Blotting-SDS-PAGE 
with a goat polyclonal antibody that would recognize BPTI.  
Deadmond et al (57) optimized the procedure for the induction of protein 
expression in BL21(DE3) cells. Fresh, sterilized TB broth with carbencillin (50 µl/ml) and 
glycerol would be used to culture the p-LAGC-EAK10-BPTI DNA shaking at 300 rpm in a 
37°C incubator until the A600 (absorbance) reaches 1.5-2.0. Next, the temperature is 
decreased to 25°C and the culture is allowed to continue incubating overnight. The next 
day, the cultures would be transferred into 1-L bottles and centrifuged at 3000 x g for 25 
minutes at 4°C. The supernatant would be decanted off and the cells washed with 250 
ml of ice cold TBS/Azide solution. This solution is a Tris saline based azide often used as 
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blocking buffer in western blotting assays. It is used here to remove any impurities that 
may be present. It is composed of 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, and 0.02% 
NaN3. The cells are centrifuged again for 25 minutes at 3000 x g at 4°C. Next, after the 
supernantant is decanted, the cell pellets should be weighed. They are then frozen at -
80 C for an hour or more. Next the pellets should be thawed at 37°C. Then, 50 ml of lysis 
buffer per gram of cell pellet should be added. The lysis buffer is a mixture of 20 mM 
Tris-HCl, 100 mM NaCl, 1% Triton X-100, 0.02% NaN3, and 1 mg/ml of lysozyme. The re-
suspended cell pellets should be mixed well then incubated on a rocker at 4°C for one 
hour. Next, poly-ethylamine solution should be added at a final concentration of 0.1% 
and mixed well. This is allowed to stand at 4°C for 10 minutes. The poly-ethylamine 
solution is composed of 5% (w/v) poly-ethylenimine in water and NaN3 concentrated at 
0.02%. The cells are centrifuged at 3000 x g for 25 minutes at 4°C. If clarity is not 
achieved, it is suggested that the cells be treated with 5 µg/ml DNAsel for at least 20 
minutes and centrifuged at 14,000 x g for 25 minutes at 4°C. The crude cell lysate 
yielded from this centrifugation should contain the BPTI protein. 
After detection by SDS-PAGE (sodium dodecyl polyacrylamide gel 
electrophoresis), the next step would be purification of the p-LAGC-EAK10-BPTI inhibitor 
ruler using affinity chromatography with trypsinized columns. SDS-PAGE works by 
separating proteins based on molecular weights using gel electrophoresis. Because 
proteins with differing molecular weights usually have differing charges as well, 
separating them on an electrical field requires that the charges all be negative such that 
they migrate at the same time on the gel (111). The SDS detergent is used to do this.  
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Neuenschwander et al also provided proof-of-principle methods for expression and 
purification of the membrane-tethered BPTI constructs. Expression and purification can 
be done by the methods these researchers used in a bacterial system to engineer a 
construct containing a lipid-tethered inhibitors extending 75Å above the membrane 
surface (57). Trypsin is used because as mentioned previously, serine proteases are very 
similar to trypsin. BPTI and trypsin have a very high affinity for one another. This means 
that any non-specific proteins in the cell lysate will elute out leaving only BPTI. Trypsin 
must be covalently bound to the column using techniques adapted from the BioRad™ 
Activated Immunoaffinity Chromatography kit. Then, the 10-ml column is equilibrated 
with trypsin. A minimum of 5 column volumes of equilibration buffer (20 mM Tris-HCl, 
100 mM NaCl, and 0.1% Triton-X100) is flowed over the column at a flow rate of 1 ml/40 
seconds. Then, the tubing containing the crude cell lysate should be loaded and flowed 
over the column at a rate of 1 ml/ 2.5 minutes. The flow-through should be saved 
because it should contain the desired product. About 50 ml of wash buffer (1 mM Tris-
HCl, 100 mM NaCl) should be loaded into the tubing and run over the column at 1 
ml/min. A high-salt wash removes any non-specific proteins that may bind to the 
column leaving only BPTI theoretically. Next, a fraction collector with 40 tubes should be 
set up. Each tube should contain 20 µl of 1M Tris-HCl to neutralize eluate upon 
collection. A fraction collector for 1 ml fractions should also be set up. Next, the tubing 
should be filled with elution buffer containing 10 mM HCl and 500 mM KCl. This elution 
buffer should be flowed over the column at a flow rate of 1 ml/min. Eluate should be 
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collected in the fraction tubes that were set up. These fractions can be read at A280 in a 
quartz cuvette. The relevant fractions should be kept and the irrelevant ones discarded.  
Once these steps have been completed, the p-LAGC-EAK10-BPTI inhibitor ruler 
will be relipidated and verified by gel filtration chromatography as described previously. 
Then, it should be ready for use to assist in the determination of the optimal reactive 
height for FXa alone as well as the prothrombinase complex (including fXa, fVa, and Ca2+). 
Using an equilibrium-based chromogenic enzyme assay, researchers could measure the 
rates and extent of inhibition for both FXa and the FXa/pro-coagulant complex. These 
experiments can be used to determine the reactivity of the complex to each modified 
inhibitor.  As described previously, experiments such as this have been carried out 
successfully by a number of researchers including Deadmond et al (57).  
Comparing the reactivity for this inhibitor at a height of 70Å off the membrane 
surface will provide insight into the elasticity (ability to reach the cell surface) of these 
complexes, as well as suggest potential optimal reactive conformation of the fXa 
complex. Reactivity at 70Å will indicate the level at which fXa is inhibited from the 
membrane surface because this is the height previously predicted to be the location of 
the active site (57).  As the height of this inhibitor ruler is adjusted, the height at which 
the inhibitor is the most reactive can be determined. Also, the height that is too short to 
cause inhibition can be determined. This information is indicative of how close to the 
simulated vessel surface fX can reach. This information will give confirmation as to the 
conclusions about fXa topography and exactly how it carries out its role in fibrin clot 
deposition.  
122 
 
Enzyme Reactivity Experiments 
  Rates of inhibition will be measured using solution-phase and surface-based 
equilibrium inhibition.  Solution-phase enzyme inhibition assay and surface-based 
enzyme inhibition can be used to characterize inhibitor activity (i.e. its Ki and inhibitory 
potential) as compared its native state. Using both of these experiments will indicate fXa 
enzymatic activity as it floats in solution as well as its activity when BPTI is attached to 
the membrane surface. As the study continues, site-directed mutagenesis can be used 
to generate p-LAGC-EAK-BPTI constructs with one fewer linker at a time to determine 
the range of optimal reactivities of FXa.  
Solution-phase equilibrium inhibition 
Purified recombinant BPTI should be incubated with trypsin for 30 minutes or 
more until equilibrium is reached. Then, a chromogenic substrate can be added to 
measure enzymatic activity.  A similar experiment using membrane-bound BPTI/fXa and 
soluble (free-floating) BPTI/fXa will need to be performed as well. The Ki of BPTI/trypsin, 
anchored BPTI/fXa, and soluble BPTI/fXa will be compared to one another. These 
comparisons will indicate whether or not the predicted reactivity height was accurate. 
 Rates can be recorded and plotted in comparison to the inhibitor concentration 
to calculate the Ki. Data from the inhibition plots/graphs derived from a series of slope 
calculations can be used to examine fXa and prothrombinase complex reactivity. A 
comparison of the modified and unmodified inhibitor could provide some information 
on inhibitory activity and the effect of the linker region within the engineered construct. 
123 
 
Solution-phase equilibrium as described above can be used to measure fXa 
reactivity in the presence of un-anchored BPTI. Using anchored BPTI is a plausible 
experiment too, as it can be done using only the fXa catalytic head and measuring 
activity of BPTI attached to a neutral phospholipid surface to ensure the process is not 
altered by a negative membrane surface. Ki values obtained from each set of inhibitor 
rulers can be compared. It is important to ensure that modifications added to BPTI did 
not interfere or alter factor activity and also to correct any differences recorded 
between the modified and unmodified versions of the inhibitor.  
Surface-based equilibrium inhibition  
Each isolate of the inhibitor complexes can be incorporated separately into 
liposomes for the purposes of comparing the inhibition at variable-lengths. These 
liposomes will contain percentages of phosphatidyl choline (PC) (roughly 90%) and 
phosphatidylserine (PS) (roughly 10%) necessary for optimal binding of fXa. Smith & 
Morrissey developed the protocol we will use to construct the liposomes by way of 
detergent removal from lipid-protein mixture using adsorbent beads (112). The fXa, lipid 
vesicles containing recombinant BPTI, and pro-thrombinase complex members fVa and 
Ca2+ can be added and incubated with the membrane. Once this forms the pro-
coagulant complex and reaches equilibrium, a chromogenic substrate will be added and 
absorbance measured at 405 nm. This experiment takes place over a monitored time 
frame to establish the initial rate of substrate hydrolysis and indicate the remaining 
enzyme activity when equilibrium is reached. Rates recorded during this experiment can 
be plotted as described previously. Analysis regarding the ratio of anchored BPTI/fXa and 
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soluble BPTI/fXa Ki rates will assist in making conclusions about the optimal height of 
active sites above the membrane. For instance, a Ki ratio of greater than 1 suggests a 
non-optimal distance separating BPTI and the fXa active site. Conversely, a Ki ratio of 
lesser than or equal to 1 indicates an optimal distance is reached. Any changes noted 
between these two data sets are also helpful with further data analysis on the proximity 
of BPTI and the FXa active site. 
Clinical Significance 
Venous thromboembolism, deep vein thrombosis, and other thrombotic 
disorders is the cause of over 100,000 deaths each year (113). Patients with these 
conditions and prone to atrial fibrillation are at the highest risk of death as a result of 
the anticoagulant treatment they need to maintain hemostasis. As mentioned, current 
treatments for thrombotic disorders are limited due to the specificity of drug targets 
and effective medical techniques. Clinicians are currently prescribing thrombotic 
patients warfarin, low molecular weight heparin, protease inhibitors, and other vitamin-
K inhibitors. However, many of these treatments lack specificity in that each of them 
target more than one portion of the process. Whereas research indicates direct fXa or 
thrombin anticoagulants are much more effective at inhibiting harmful clotting.  These 
two components are the largest proponents of coagulation. Therefore, specifically 
targeting one or the other has been shown to greatly reduce clotting without disturbing 
other biochemical processes. A review published by S. Aditya in the Journal of Post-
graduate Medicine reports newer anticoagulant treatments are effective at targeting 
specific parts of the coagulation process but put the patient at risk of excessive 
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coagulation as well. Though these treatments are an improvement, they are still not as 
ideal as targeting fXa (114).  
Information characterizing fXa topography more clearly would greatly improve 
researchers’ ability to generate drugs which can be used to target the two most 
committed steps to coagulation, activation of fXa and thrombin bursts. Data obtained 
from these experiments will be invaluable in gaining knowledge about the rational 
design of effective membrane-based inhibitors. In addition, findings could be very useful 
in clinical medicine as well in that these membrane-based inhibitors could be used for 
the treatment of thrombosis and other thrombotic disorders. The information will 
provide some guidance on specificity in regard to effective distances of inhibition on the 
membrane surface which could lead to a number of clinical applications. Among these 
applications are drugs designed to work more accurately to prevent adverse responses 
to thrombosis symptoms.  
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Appendix I: Truncated pET11d Vector DNA and Protein Sequence 
HINDIII NCOI BAMHI XbaI 
 
Serial Cloner 2.6: Alignment pET11d Sequence 
 
Similarity: 5674/5674 (100.00 %) 
 
             F  S  C  L  T  A  Y  H  R  *  A  L  M  R  *  F  I  T  V  K   
pET11d       ttctcatgtttgacagcttatcatcgataagctttaatgcggtagtttatcacagttaaa  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
pET11d       ttctcatgtttgacagcttatcatcgataagctttaatgcggtagtttatcacagttaaa  60 
 
 
             L  L  T  Q  S  G  T  V  Y  E  I  *  Q  C  A  H  R  H  P  R   
pET11d       ttgctaacgcagtcaggcaccgtgtatgaaatctaacaatgcgctcatcgtcatcctcgg  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
pET11d       ttgctaacgcagtcaggcaccgtgtatgaaatctaacaatgcgctcatcgtcatcctcgg  120 
 
 
             H  R  H  P  G  C  C  R  H  R  L  G  Y  A  G  T  A  G  P  L   
pET11d       caccgtcaccctggatgctgtaggcataggcttggttatgccggtactgccgggcctctt  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
pET11d       caccgtcaccctggatgctgtaggcataggcttggttatgccggtactgccgggcctctt  180 
 
 
             A  G  Y  P  D  I  V  P  P  F  S  K  K  P  L  K  T  R  L  E   
pET11d       gcgggatatccggatatagttcctcctttcagcaaaaaacccctcaagacccgtttagag  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
pET11d       gcgggatatccggatatagttcctcctttcagcaaaaaacccctcaagacccgtttagag  240 
 
 
             A  P  R  G  Y  A  S  Y  C  S  A  V  A  A  A  N  S  A  S  F   
pET11d       gccccaaggggttatgctagttattgctcagcggtggcagcagccaactcagcttccttt  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
pET11d       gccccaaggggttatgctagttattgctcagcggtggcagcagccaactcagcttccttt  300 
 
 
             R  A  L  L  A  A  G  S  D  P  F  A  V  H  Q  S  C  *  P  W   
pET11d       cgggctttgttagcagccggatccgacccatttgctgtccaccagtcatgctagccatgg  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
pET11d       cgggctttgttagcagccggatccgacccatttgctgtccaccagtcatgctagccatgg  360 
 
 
             Y  I  S  F  L  K  L  N  K  I  I  S  R  G  E  L  L  S  A  H   
pET11d       tatatctccttcttaaagttaaacaaaattatttctagaggggaattgttatccgctcac  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
pET11d       tatatctccttcttaaagttaaacaaaattatttctagaggggaattgttatccgctcac  420 
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Appendix II: BPTI DNA & Protein Sequence  
Serial Cloner 2.6: Alignment BPTI Sequence 
 
               W  M  R  P  D  F  C  L  E  P  P  Y  T  G  P  C  K  A  R  I 
BPTI         CATGGATGCGTCCGGACTTCTGCCTCGAGCCGCCGTACACGGGTCCCTGCAAAGCGCGCA  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
BPTI         CATGGATGCGTCCGGACTTCTGCCTCGAGCCGCCGTACACGGGTCCCTGCAAAGCGCGCA  60 
 
 
               I  R  Y  F  Y  N  A  K  A  G  L  C  Q  T  F  V  Y  G  G  C 
BPTI         TCATCCGTTACTTCTACAACGCTAAAGCAGGCCTGTGCCAGACCTTCGTTTACGGTGGCT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
BPTI         TCATCCGTTACTTCTACAACGCTAAAGCAGGCCTGTGCCAGACCTTCGTTTACGGTGGCT  120 
 
 
               R  A  K  R  N  N  F  K  S  A  E  D  C  M  R  T  C  G  G  A 
BPTI         GCAGAGCTAAGCGTAACAACTTCAAATCCGCTGAAGACTGCATGCGTACCTGCGGTGGTG  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
BPTI         GCAGAGCTAAGCGTAACAACTTCAAATCCGCTGAAGACTGCATGCGTACCTGCGGTGGTG  180 
 
 
               *  *  X   
BPTI         CTTAATAAT  189 
             ||||||||| 
BPTI         CTTAATAAT  189 
 
 
 
 
 
  
130 
 
Appendix III: Oligonucleotides  
 
LINKER—171 base pairs 
MolecularWeight—105,725 g/mol 
Forward: 
5’/5Phos-
GATCCGAAGCGGCGGCGAAAGAAGCGGCGGCGAAAGAAGCGGCGGCGAAAGAAGCGGCGGCGA
AAGAAGCGGCGGCGAAAGAAGCGGCGGCGAAAGAAGCGGCGGCGAAAGAAGCGGCGGCGAAAG
AAGCGGCGGCGAAAGAAGCGGCGGCGAAAGGTGGTGGTGGTAGCC-3’ 
Reverse: 
5’/5Phos-
CATGGGCTACCACCACCACCTTTCGCCGCCGCTTCTTTCGCCGCCGCTTCTTTCGCCGCCGCTTCTTTCG
CCGCCGCTTCTTTCGCCGCCGCTTCTTTCGCCGCCGCTTCTTTCGCCGCCGCTTCTTTCGCCGCCGCTTC
TTTCGCCGCCGCTTCTTTCGCCGCCGCTTCTTTCGCCGCCGCTTCG–‘3 
ProteinSequence: 
SEAAAKEAAAKEAAAKEAAAKEAAAKEAAAKEAAAKEAAAKEAAAKEA AAKGGGGSX  
 
  
LAGC—75 base pairs 
Molecular Weight—46,366 g/mol 
Forward: 
5’/5Phos- AGC TTA TGA AAA CCA AAA ACT TTC TTC TTT TTT GTA TTG CTA CAA ATA TGA TTT 
TTA TCC CCC TGG CTG GAT GTG-3’ 
Reverse: 
5’/5Phos- GAT CCA CAT CCA GCC AGG GGG ATA AAA ATC ATA TTT GTA GCA ATA CAA AAA 
AGA AGA AAG TTT TTG GTT TTC ATA-3’ 
Protein Sequence: 
LMKTKNFLLFCIATNMIFIPLAGCX  
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BPTI—189 base pairs 
MolecularWeight—116,819 g/mol 
Forward: 
5’/5Phos-
CATGGATGCGTCCGGACTTCTGCCTCGAGCCGCCGTACACGGGTCCCTGCAAAGCGCGCATCATCCG
TTACTTCTACAACGCTAAAGCAGGCCTGTGCCAGACCTTCGTTTACGGTGGCTGCAGAGCTAAGCGT
AACAACTTCAAATCCGCTGAAGACTGCATGCGTACCTGCGGTGGTGCTTAATAAT-3’ 
Reverse: 
5’/5Phos-
CTAGATTATTAAGCACCACCGCAGGTACGCATGCAGTCTTCAGCGGATTTGAAGTTGTTACGCTTAG
CTCTGCAGCCACCGTAAACGAAGGTGTGGCACAGGCCTGCTTTAGCGTTGTAGAAGTAACGGATGA
TGCGCGCTTTGCTGGGACCCGTGTACGGCGGCTCGAGGCAGAAGTCCGGACGCATC-3’ 
ProteinSequence: 
WMRPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCG
GA**X  
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Appendix IV: p-LAGC-EAK10 Plasmid DNA 
Serial Cloner 2.6: Alignment p-LAGC-EAK10 Sequence 
 
Similarity: 5526/5526 (100.00 %) 
 
               L  M  K  T  K  N  F  L  L  F  C  I  A  T  N  M  I  F  I  P 
p-LAGC-EAK10 agcttatgaaaaccaaaaactttcttcttttttgtattgctacaaatatgatttttatcc  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
p-LAGC-EAK10 agcttatgaaaaccaaaaactttcttcttttttgtattgctacaaatatgatttttatcc  60 
 
 
               L  A  G  C  G  S  E  A  A  A  K  E  A  A  A  K  E  A  A  A 
p-LAGC-EAK10 ccctggctggatgtggatccgaagcggcggcgaaagaagcggcggcgaaagaagcggcgg  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
p-LAGC-EAK10 ccctggctggatgtggatccgaagcggcggcgaaagaagcggcggcgaaagaagcggcgg  120 
 
 
               K  E  A  A  A  K  E  A  A  A  K  E  A  A  A  K  E  A  A  A 
p-LAGC-EAK10 cgaaagaagcggcggcgaaagaagcggcggcgaaagaagcggcggcgaaagaagcggcgg  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
p-LAGC-EAK10 cgaaagaagcggcggcgaaagaagcggcggcgaaagaagcggcggcgaaagaagcggcgg  180 
 
 
               K  E  A  A  A  K  E  A  A  A  K  E  A  A  A  K  G  G  G  G 
p-LAGC-EAK10 cgaaagaagcggcggcgaaagaagcggcggcgaaagaagcggcggcgaaaggtggtggtg  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
p-LAGC-EAK10 cgaaagaagcggcggcgaaagaagcggcggcgaaagaagcggcggcgaaaggtggtggtg  240 
 
 
               S  P  R  G  E  L  L  S  A  H  N  S  P  I  V  S  R  I  N  F 
p-LAGC-EAK10 gtagccctagaggggaattgttatccgctcacaattcccctatagtgagtcgtattaatt  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
p-LAGC-EAK10 gtagccctagaggggaattgttatccgctcacaattcccctatagtgagtcgtattaatt  300 
 
 
               A  G  S  R  S  R  S  S  T  P  D  A  S  W  P  A  S  P  A  P 
p-LAGC-EAK10 tcgcgggatcgagatctcgatcctctacgccggacgcatcgtggccggcatcaccggcgc  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
p-LAGC-EAK10 tcgcgggatcgagatctcgatcctctacgccggacgcatcgtggccggcatcaccggcgc  360 
 
 
               Q  V  R  L  L  A  P  I  S  P  T  S  P  M  G  K  I  G  L  A 
p-LAGC-EAK10 cacaggtgcggttgctggcgcctatatcgccgacatcaccgatggggaagatcgggctcg  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
p-LAGC-EAK10 cacaggtgcggttgctggcgcctatatcgccgacatcaccgatggggaagatcgggctcg  420 
 
 
               T  S  G  S  *  A  L  V  S  A  W  V  W  W  Q  A  P  W  P  G 
p-LAGC-EAK10 ccacttcgggctcatgagcgcttgtttcggcgtgggtatggtggcaggccccgtggccgg  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
p-LAGC-EAK10 ccacttcgggctcatgagcgcttgtttcggcgtgggtatggtggcaggccccgtggccgg  480 
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Appendix V: Sequencing Data 
Downloaded from www.retrogen.com/downloadresults 
 
  
Display Results for 26796-2 AI T 
3730 Chromatogram 
I Utilities II Next N 1~1 Data II Screen I H~ V~ 
N N N NN NNN N N NN N N N N N C 
I Sequence Text II Ph red Sequence II Clear Text Am I 
Use the text box to Copy contents to the clipboard. 
NNNNNNNNNNNNNNNCNCTAGANTAATTTTGTTTAACTTT~AG~-~GGAGATATAC~~TC~~.CTACCACCACCACCTTTCG 
CCGCCGCTTCTTTCGCCGCCGCTTCTTTCGCCGCCC<TTCTTTCGCCGCCGCTTCHTCGCCGCCGCTTCTTTCGCCGCCGC 
TTCTTTCGCCGCCGCTTCTTTCGCCGCCGCTTCTTTCC.CCC.CCC.c!TCTTTCC.CCC.CCGCTTCTTTCGCCGCCGCTTCGGAT 
CCACATCCAGCCAGGGGGATAAAAATCATATTTGTAGCAATACk~~~~~G~-~G~~-~GTTTTTGGTTTTCATAAGCTTATCGA 
TGATAAGCTGTCAAACATGAGAATTCTTGAAGACGAAAC.C.C.CCTCGTGATACGCCTAIITTTATAGGTTAATGTCATGATAA 
TAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCC.CC-G~-~CCCCTATTTGTTTATTTTTCTAAATACATTC 
AAATATGIATCCGCI CAI GAGACAAIAACCCTGATAAAIGCTTCAAIAAIAIIGAAAAAGGAAGAGTATGAGIAIICAACAI 
TTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTC.CCTTCCTGTTTTTC-cTCACC~~G~~-~CGCTGGTG~AAGTAAAAG 
ATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCk~CAGCGGIAAG.!!.TCCTTGAGAGTTITCGCCC 
CGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTC-cTAIGIC-c-cGCGGTATTAICCCGTGTTGACGCCGGGCAAGAG 
C~ACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAG~~~AGCATCTTACGGATGGCA 
TGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGAIAACACTC.CC.C.CCAACTTACTTCTGACAACGATCGGAGG 
ACCGAAGGAGCTAACCGCTTTTTTNNACANATGGGGGATCATGNAACTCGCCITGATCGTTGGG~ACCGGAGCTGAATGAAN 
NATACCAAACGANNNNNNNNGNNNNCNCGATGCCTGNAGCAANGGCAACAACNNN 
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